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1. INTRODUCTION 
The purpose of this experiment was to determine if transcranial Doppler sonog­
raphy (TCD) could be used in the dog to noninvasively measure changes in cerebral 
blood flow (CBF) resulting from a low-level exposure to the commonly used insec­
ticide deltamethrin. TCD provides a means of noninvasively measuring blood flow 
velocity in the brain. Since changes in CBF may occur before behavioral or clini­
cal symptoms of chemically-induced toxicosis [5. 7, 8], a means of measuring these 
changes could potentially be used as a screening procedure for early detection of ex­
posure to hazardous substances. If changes in CBF can be detected by TCD before 
the occurrence of behavioral or clinical signs, then interdictive measures could be 
initiated very early in the exposure at a time when the effects of the toxicosis may 
be either minimal or reversible. 
For TCD to be a useful method for detecting exposure to hazardous chemicals, 
it should be sensitive to chemically induced changes in CBF at exposure levels at 
or near established threshold limit values (TLVs) and be reliable and easy to use. 
This study sought to demonstrate that TCD can be used to noninvasively measure 
changes in C'BF in the greyhound dog caused by low-level exposure to the widely 
used pyrethroid insecticide deltamethrin. 
Several commercial TCD instruments available today are small, portable de­
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vices that can be used by a trained registered vascular technician (RVT). Although 
TCD is a relatively new technique, it is finding use in an growing number of clinical 
applications, for example, 
• in the diagnosis of cerebral vascular disease (including stenoses). 
• in the determination of arterial-venous malformations (AV'Ms). 
• in intraoperative monitoring (as during open-heart surgery and carotid en-
darterectomy). 
• in the detection of vasospasm due to subarachnoid hemorrhage, and 
• in the study of the effects of microgravity and Space Adaptation Syndrome 
aboard NASA's space shuttles. 
To conduct this experiment, a computer-based system capable of detecting chem­
ically induced changes in C'BF in the dog was constructed. The system used TCD 
to noninvasively measure changes in C'BF. Deltamethrin was dissolved in glycerol-
formal^ solvent and administered intravenously via a cannula in the jugular vein at 
dosage levels of 5% and 10% of the LD^Q value (as determined by a dose-response 
pilot study) to 12 dogs. Since the changes resulting from low-level deltamethrin ex­
posure are subtle and occur over several minutes (rather than beat-by-beat changes), 
the data was stored on a PC for off-line post processing. These data included mean 
blood flow velocity (MBFV) in the middle cerebral artery, mean arterial blood pres­
sure (MAP) in the aorta, end tidal CO2 ( pC'Oo ), mean heart rate (MHR) and concen­
tration of deltamethrin in the blood. Data were measured during control, glycerol-
^75% 5-hydroxy-l,3-dioxane and 25% 4-hydroxymethyl-i.3-dioxolane. 
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formal and exposure (deltamethrin in glycerol-formal) periods according to a ran­
domized block factorial design. In addition to the aforementioned parameters, four 
additional parameters were calculated using the blood flow velocity waveform. They 
were systolic-to-diastolic ratio (SDR),. Pourcelout pulsatility index (PPI). Gosling 
pulsatility index (GPI) and systolic upstroke (SU). An analysis of variance was pre­
formed on each parameter to determine if there were significant differences among 
the three treatment groups. 
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2. BACKGROUND 
Proper functioning of the central nervous system (CNS) depends upon adequate 
cerebral blood flow for the delivery of oxygen, glucose and other nutrient materials 
and the removal of carbon dioxide and other metabolic byproducts from the brain. 
Blood flow to the brain is highly regulated and, therefore, the brain is highly suscep­
tible to disturbances of the blood supply [20]. 
2.1 Regulation of Cerebral Blood Flow 
CBF is regulated by changes in arterial blood pressure and cerebral blood flow re­
sistance. Arterial blood pressure is regulated by circulatory reflexes (i.e., the barore-
ceptor reflex and the cerebral ischemic reflex). Cerebral blood flow resistance is 
subject to several types of regulation (i.e., blood viscosity, neural regulation and 
autoregulation). CBF is approximately linearly proportional to pCOo while it is rel­
atively independent of arterial pressure within normal physiological limits 17] (see 
Figure 2.1). For example, inhalation of 5% COo increases CBF by .509c and breathing 
7% COg doubles C'BF. Conversely, breathing 100% Oo lowers CBF about 13%: 10% 
Og raises it 35% (see Table 2.1) [17!. In most situations. CBF is positively correlated 
with glucose metabolism, i.e., an increase in metabolic rate (M) gives rise to an 
increase in glucose utilization (i^^Qluc) ^"(1 Rn increase in cerebral blood flow (CBF) 
•5 
Table 2.1: Summary of qualitative effects of Oo and COo on cerebral blood flow 
[20] 
Direction of Change 
5% COg (hyperatmospheric) r 
7% CO2 (hyperatmospheric) TT 
10% Oo (subatmospheric) TT 
100% Og (hyperatmospheric) 1 
[4] or 
I  M =. f  =1  CBF.  
2.1.1 Influences of selected drugs and external stimuli on CBF 
CBF is sensitive to many drugs. For example, CBF tends to decrease under 
general anesthesia (slowing of metabolism) while large doses of epinephrine tend 
to increase CBF. Barbiturates {i.e., pentobarbital) are potent vasoconstrictors and 
can cause a potentially large decrease in CBF [5i. On the other hand, the inhalation 
anesthetics (i.e., halothane) as a group are unique in that they all appear to uncouple 
the normally tight relationship between CBF and Therefore, halothane (used 
in this experiment) would be expected to increase CBF causing a corresponding 
decrease in [21]. 
j ,  . =  HALOTHANE =•  \  CBF 
In addition, CBF is sensitive to many external stimuli. For example, blood flow in 
the occipital lobe increases during visual stimulation and blood flow in motor areas 
increases during limb movements [17|. 
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Figure 2.1: Effects of pCOg (A) and arterial pressure (B) on cerebral blood flow 
2.2 Measurement of Cerebral Blood Flow 
Research in neurotoxicology seeks to determine the consequences of neurotox­
ic ant exposure on central nervous system (CNS) function. Methods for examining 
CNS function may vary from the behavioral to the molecular level. The functional 
ance and temperature regulation which are in turn dependent upon cerebral blood 
flow. Although it is well known that several neurotoxicants alter CBF [19, 22, 28], 
the use of CBF measurement in neurotoxicology research has been very restricted be­
cause CBF has been difficult to measure. Indeed, many methods currently available 
require very sophisticated equipment and are extremely costly. 
Methods for measuring blood flow in the brain can be divided into invasive and 
noninvasive  techniques .  They can be  fur ther  subdivided in to  area  measurements  { i .e . ,  
rCBF) or point measurements {i.e., BFV). 
(201 
capacity of the CNS is dependent upon nutrient exchange, waste removal, fluid bal-
I 
2.2.1 Differences between rCBF and CBF 
Typically, blood flow to and/or from a particular organ is reported in terms of 
the mass of tissue perfused by a given volume of blood per unit time. In the brain, this 
type of measurement is called the regional cerebral blood flow (rCBF) because 
it measures the blood flow supplying a particular region of the brain, for example, 
the cortex or the hypothalamus. It has dimensions of volumetric flow per unit mass. 
i.e., ml/min/mg. 
Flow through a particular vessel, regardless of the area that it serves, is called 
cerebral blood flow (CBF). CBF is a volumetric flow and thus has typical dimen­
sions of ml/min. 
2.2.2 Relationship between BFV and CBF 
Blood flow velocity (BFV) is the average instantaneous velocity of blood 
flowing through a  given cross-sect ional  area  of  a  vessel  a t  a  given t ime.  BFV is  not  
the same as CBF. They can be related through the continuity equation as: 
C B F  =  B F V  X .4 
where .4 is the cross-sectional area of the lumen of the vessel of interest. It should 
be noted that .4 is rarely known in the cerebrovascular system. However. .4 seems to 
depend more on intracranial pressure (ICP) than CBF (which is not usually the case 
outside the cerebrovascular system), especially for the large cerebrovascular vessels. 
i.e., the circle of Willis and its branches (see page 17) [Ij. ICP is constant except 
after a cerebral vascular accident (CVA). for example, in head trauma resulting in 
subdural hematoma and increased fluid pressure on the brain. Therefore, if ICP does 
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not significantly change, then the cross-sectional area of a vessel will not change and. 
in general, an increase in BFV will result in a corresponding increase in CBF and 
vice versa, or 
BFV oc CBF.  
2.2.3 Invasive measurements of rCBF 
The most commonly used invasive technique to measure regional cerebral blood 
flow is the radioactive microsphere technique. This method involves sacrificing the 
subject to obtain a measurement thus it is strictly limited to use in research animals. 
Small latex spheres (or glucose molecules) are labeled with a radioactive tag 
iodoantipyrine or 2-deoxyglucose) and injected into an extracranial vessel (usually 
the internal carotid artery). .A.iter a specified time, the animal is sacrificed and 
various parts of the brain are identified and removed. The amount of radiation 
detected in each -sample can be related to the number of microspheres in the area 
which can in turn be correlated with rCBF for that area[9, 27]. .\s a consequence 
of having to sacrifice the animal, this method has the significant disadvantage that 
only one measurement can be obtained from each animal, thus, a large population is 
required. This technique is best suited for small animals (i.e., rats and mice) which 
have relatively small brains and are inexpensive to obtain and house. 
2.2.4 Invasive measurements of CBF at a point 
To invasively measure CBF at a point involves surgically opening the skull, 
reflecting the brain tissue (if necessary) and using an electromagnetic flow meter. 
Doppler flow meter or similar device directly on the vessel of interest. This technique 
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is best suited for studying vessels on the surface of the brain, for example, the lateral 
middle cerebral arteries or the very small pial arteries. 
An interesting use of TCD in dogs involves removing a piece of skull and placing 
a 8 MHz CW-Doppler probe directly on the dura to insonate the vessels of the circle 
of Willis, etc., (see page 29). Although this approach may be effective, it can hardly 
be considered noninvasive and is certainly not transcranial. 
2.2.5 Noninvasive measurements of rCBF 
There are several noninvasive techniques for measuring regional cerebral blood 
flow. Such methods include: positron emission tomography (PET) scanning and mag­
netic resonance imaging (MRI). ^^^Xe gas is typically introduced into the breathing 
stream (or dissolved and injected into the internal carotid artery) and. due to its 
high diffusion coefficient, it enters the brain where it may be detected by an array of 
sensors placed around the head. .As in the microsphere technique described above, 
the amount of ^^^Xe present can be correlated to the rC'BF for that area 4. 14. 20t. 
These methods are expensive but have become routinely used in human medicine. 
2.2.6 Noninvasive measurements of CBF at a point 
Transcranial Doppler sonography is a new methodology which uses ultrasound to 
noninvasively measure blood flow velocity (BFV) at a point in a blood vessel within 
the brain. This method is described in detail in chapter 3. 
-Another interesting technique is called quantitative angiography. In this 
technique, a radio-opaque dye is injected into a vessel which makes the blood flow 
visible on a fluoroscope ]4j. This information is fed into a computer and the volumetric 
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flow rate may be determined. This method is gaining in popularity in the human 
medical field. 
2.3 Toxicology 
To test the validity of TCD in this study, a chemical was chosen that had already 
been shown to alter CBF in lower mammals. Deltamethrin is a synthetic pyrethroid 
which had previously been shown to alter CBF in rats [7, 17]. It is widely used 
as an insecticide throughout the world and is commonly found in commercial and 
household products. 
2.3.1 Measurement of toxicity 
Deltamethrin is one of the most potent pyrethroids and is commonly used in 
agricultural and household insecticides. The relative toxicities of various substances 
are often compared by their LD^q valuesk The LD^q of deltamethrin in dogs is 
.3.440 mg/kg i.v.; in rats, it is 2-4 mg/kg; and in insects, it is 0.03 mg/kg (or 0.03 
ng per insect) [7]. Threshold limit values'^ (TLVs), as well as permissible exposure 
limits^ (PELs), have not yet been established for deltamethrin. 
^LDgQ (lethal dosage -50%) is the dosage that if given to 100 animals. 50 of them 
will die [19]. 
"ACGIH annually publishes recommended Threshold Limit Values which are air­
borne concentrations of substances and conditions under which it is believed that 
nearly all workers may be repeatedly exposed day after day without adverse efleet 
[26]. 
•^OSHA is responsible for establishing legally enforceable Permissible Exposure 
Limits for industry in the United States. 
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2.3.2 Pyrethroids . 
The synthetic pyrethroids are a class of chemical insecticides that are highly toxic 
to a wide range of insects but are of relatively low toxicity to mammals. However, 
if absorbed in sufficient quantities, pyrethroids are also toxic to mammals [16l. In 
addition, pyrethroids degrade leaving no residues in the biosphere. Consequently, 
pyrethroids are commonly used to control a variety of agricultural and household 
pests. At present, the most commonly used pyrethroids are deltamethrin, fenvalerate 
and cypermethrin [13, .30]. These compounds are known to greatly affect CBF. 
2.3.2.1 Clinical classification of pyrethroids Pyrethroids can be divided 
into two types based on the symptoms they produce [llj. Type / pyrethroids pro­
duce pr imar i ly  t remor  associa ted  wi th  increased sensi t iv i ty  to  external  s t imul i .  Type  
II produce profuse salivation and choreoathetosis (withering convulsions). Some 
pyrethroids produce a mixture of the Type /and Type //syndromes 119;. .At sublethal 
doses, the effects of pyrethroid intoxication are reversible, i.e.. an animal can exhibit 
characteristic signs of pyrethroid poisoning and then fully recover 19'. 
2.3.2.2 Mechanism of action of pyrethroids All pyrethroids interact 
with sodium channels in excitable tissues [15, 31]. They do so by prolonging sodium 
current evoked by membrane depolarization [19, 25]. It has been suggested that 
the sodium channel is a likely site of action in mammals for pyrethroids that evoke 
both  Type  /  and Type  / /  behaviors  [19! .  One dis t inct ion between Type  /  and Type  
II pyrethroids is the duration of the prolonged sodium current. In insects and am­
phibians, Type / pyrethroids hold sodium channels open for relatively short periods 
12 
C—CK COOCH 
1 
L CS Br 
Figure 2.2: Structure of deltamethrin, 3-(2,2-dibromoethenyl) 2,2-dimethyl cyclo-
propanecarboxylic acid cyano(3-phenoxyphenyl)-methyl ester 
(msec), and Type //pyrethroids for longer periods (sec) [19]. Although this temporal 
difference between Type / and Type //compounds has been suggested to be the basis 
for the different behavioral effects observed in mammals, the magnitudes of these 
times are large compared to the times of normal synaptic events in the mammalian 
central nervous system. Deltamethrin is a Type II pyrethroid and thus holds sodium 
channels open for relatively long periods of time. 
2.3.3 Deltamethrin 
Since 1980, deltamethrin (see Figure 2.2) has been widely used throughout the 
world in the protection of crops, control of stored products and control of household 
insects [32]. It is, respectively, 100, 40 and 5-10 times as potent as DDT, parathion 
and other pyrethroids used in agriculture [6]. It is of interest to note that no clinical 
case of acute pyrethroid poisoning had been reported in the literature until outbreaks 
of acute deltamethrin and fenvalerate poisoning occurred in Chinese farm workers 
where application of pyrethroid insecticides was first started in 1982. Between 1982 
and 1988, there were 573 cases of acute pyrethroid poisoning (including 229 occu­
pational and 344 accidental poisonings) reported in the Chinese medical literature 
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alone [321. 
Although there have been several studies on the effects of pyrethroids on the 
mammalian central nervous system, there has been only one study on the effects of 
pyrethroids on the cardiovascular system [10] and one on the effects of pyrethroids 
on the cerebrovascular system [7]. 
The change in CBF in the presence of deltamethrin or any other pyrethroid is as 
yet undetermined in the dog or any other higher mammal. However, some information 
about changes in regional cerebral blood flow (rCBF) is currently available. When 
dissolved in glycerol-formal and given intravenously, the LD^q of deltamethrin was 
a s  l o w  a s  3 . 4 4  ±  0 . 6 7 m g j k g  i n  a n a e s t h e t i z e d  d o g s  ( 2 - 4  m g j k g  i . v .  i n  r a t s )  i G l .  
When administered intravenously, the toxicity of deltamethrin does not vary from 
one animal species to another [19]. In the rat, when deltamethrin (2 mgjkg i.v.) is 
administered, rCBF (as measured by technique) in 14 areas of the brain studied 
increased between 150-300% [9|. A typical sequence of behavioral changes is as 
follows: 
1. the onset of chewing at 1 minute, 
2. salivation at 2 minutes, 
... significant increases in rCBF observed at this time. 
3. body twitches at 4 minutes. 
4. head and forepaw movements at 6 minutes. 
Other than in the cerebellum, a significant increase in rC'BF was of early onset, 
occurring in rats showing salivation and chewing as the only symptoms after being 
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given deltamethrin. Low-level exposure to pyrethroids produces reversible symptoms 
in higher mammals. At higher exposure levels, the pyrethroid may cause permanent 
damage or perhaps even death. Alterations in rC'BF have been associated with 
behavioral changes in pyrethroid exposures in the rat. It is not known, however, 
whether these rCBF alterations precede behavioral changes. Given that blood flow 
to the brain is so closely regulated, any change in CBF may be seen as an early 
indication of possible deltamethrin exposure. The mechanism for this change is a 
subject which merits further investigation. 
2.4 Cerebral Vascular Anatomy 
The anatomy and blood flow in the cerebral vascular system is quite complex and 
therefore will be discussed briefly. The application of TCD to the dog is complicated 
by the slight anatomical differences between the human and canine cerebral vascu­
lar systems. However, since this study was limited to the MCA. these differences 
were not pertinent and thus will not be discussed here. Commonly used anotomical 
abréviations are summarized in Table 2/2. 
2.4.1 Extracranial anatomy 
The blood supply to the head and neck originates from the great vessels of the 
aortic arch in the superior mediastinum. After asymmetric origins, the arterial supply 
to/within the brain is generally symmetric. The aortic arch gives rise to three major 
trunk vessels: the brachiocephalic trunk (innominate artery), the left subclavian 
artery and the left common carotid artery. The brachiocephalic trunk is the first 
branch from the distal ascending aorta and divides to form the right subclavian 
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artery and the right common carotid artery. After asymmetric origins, the common 
carotid arteries ascend the anterolateral aspect of the neck in parallel and divide to 
form the internal and external carotid arteries in the mid-cervical portion of the neck. 
The subclavian arteries (providing blood supply to the arms) arise asymmetrically. 
The first major branch forms the vertebral artery. The vertebral arteries ascend the 
neck in parallel and enter the skull through the foramen magnum (see Figure 2.3). 
2.4.2 Intracranial anatomy 
The internal carotid arteries (ICA) are two of the four major arteries supplying 
the brain. They provide most of the flow to the frontal, temporal and parietal lobes. 
The ICAs pierce the dura mater anterior to the clinoid process, and each divides into 
two terminal branches: the anterior cerebral artery ( AC A) and the middle cerebral 
artery'^ (MCA). The circle of Willis is a vascular ring at the base of the brain which 
connects the two ICA systems with each other as well as with the posterior vertebral-
basilar system. 
2.4.2.1 Circle of Willis The circle of Willis provides the most important 
source of collateral circulation to the brain. It can be divided into an anterior portion 
and a posterior portion (see Figures 2.4 and 2.5). The anterior portion is composed 
of two internal carotid arteries, horizontal segments of both anterior cerebral arteries 
and the anterior communicating artery. The posterior portion is composed of the 
proximal segments of both posterior cerebral arteries and the two posterior com­
municating arteries (which arise from the IC.A). The anterior communicating artery 
'^The middle cerebral artery was the principal artery of interest in this study. 
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Table 2.2: Summary of commonly used anatomical abbreviations 
Abbreviation Artery name 
AC A Anterior Cerebral Artery 
ACoA Anterior Communicating Artery 
BA Basilar Artery 
ICA Internal Cerebral Artery 
MCA Middle Cerebral Artery 
PCA Posterior Cerebral .Artery 
VA Vertebral Artery 
(ACoA) completes the anterior portion of the circle of Willis by joining the AC As. It 
is interesting to note that only 18-20% of the general population have this balanced 
circle of Willis configuration. 
2.4.2.2 Middle cerebral artery The middle cerebral artery (MCA) sup­
plies a very extensive area, including most of the lateral surfaces of the cerebral 
hemispheres. The MCA is the larger of the two terminal branches of the ICA (recall 
the other is the .ACA). The M-1 segment extends laterally and horizontally in the lat­
eral cerebral fissure to the Sylvian fissure. The MC.A turns upward around the island 
of Reil, branching and coursing posterosuperiorly within the depths of the Sylvian 
fissure. Although branching patterns are highly variable, anomalies are uncommon. 
2.4.2.3 Additional arteries Although the MCA was the primary focus of 
this study, there are several other large arteries associated with the circle of Willis 
that, for the sake of completeness, will be briefly discussed. 
The vertebral arteries (VA) are paired arteries that enter the skull through the 
vinffnor ttrthral aritr>j, 
iXnUTT^cat^id artrry. 
A Z^tdtiU ehtbrnt arttry* 
/Poilerior uifehral arUiy, 
yerichral arUry. 
Figure 2.4: Human circle of Willis and surrounding vessels [12] 
foramen magnum and proceed anteriorly to the upper medulla where they join to form 
the basilar artery (BA) at the junction of the medulla and the pons. The BA courses 
superiorly along the ventral surface of the pons and terminates at the interpeduncular 
cistern by dividing into the posterior cerebral arteries (PCA). The PC As supply the 
temporal, parietal and occipital lobes as well as the thalamus, midbrain and other 
deep structures. 
2.4.2.4 Models Due to the complicated nature of the geometry of the ves­
sels involved in this project, two models were fabricated from greyhound dogs of 
comparable size to those used in this study to help visualize the anatomical relation-
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Figure 2.5: Canine circle of Willis and surrounding vessels (dorsal view) [2] 
ships of vessels and to help find the optimum probe placement'^. Although a small 
amount of shrinkage is expected while making these models, the shrinkage will be 
proportional in all dimensions to reflect the in vivo situation as closely as possible. 
Plasticization model: This model is an entire head with the left side completely 
intact, but the right side has the skull and soft tissues removed revealing the cerebral 
vessels on the surface of the brain (see Figure 2.6). 
Corrosion-cast model: This model shows only the skull and blood vessels, all 
other soft tissues are removed. The arterial system is shown in red and the venous 
system is shown in blue (see Figure 2.7). 
Model fabrication was done locally by an experienced veterinary anatomy 
technician. 
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Canine Cerebral Vascular Anatomy 
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CIRCLE OF WILLIS 
Anterior Cerebral Artery 
Middle Cerebral Artery 
Posterior Cerebral Artery 
Figure 2.6: Photograph showing corrosion-cast model of greyhound cerebrovascular 
system. All soft tissue is removed in this model leaving only bone, 
arteries (red) and veins (blue) intact 
Iowa Slale Unrverstt^ 
Figure 2.7: Photograph showing plasticization model of greyhound head showing 
layers of bone and soft tissue in cross-section to the circle of Willis 
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3. TRANSCRANIAL DOPPLER SONOGRAPHY 
Transcranial Doppler sonography (TCD) provides a method by which ultrasound 
is used to obtain a real-time blood velocity waveform noninvasively from one of the 
larger vessels within the brain. Traditionally, ultrasound does an excellent job of 
penetrating the soft tissues (as evidenced by its use in obstetrics, gynecology, and 
cardiology); however, it does not penetrate hard tissue (i.e., bone) nearly as easily. 
Since the brain, and therefore the blood supply to and from the brain, is nearly 
totally encompassed by the skull, ultrasound techniques could not. until recently, 
image brain tissue or measure blood flowing within the brain. 
3.1 Transmission of Ultrasound through Bone 
The problem of the acoustic properties of the skull were studied by White and 
co-workers in 1978 [.36]. The skull consists of three layers of bone which influence 
ultrasound in different manners. The middle layer (diploe) has the most important 
effect on the attenuation and scattering of the ultrasound, especially when the bony 
spicules have a diameter comparable to the wave length of the ultrasound. However, 
these spicules are absent in the temporal region where the skull is the thinnest L . 
In addition, the skull has the effect of an acoustic lens, i.e., bone tends to shorten 
the focal length of.the ultrasound beam which may decrease sensitivity to blood flow 
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in deeper vessels (i.e., 5-10 cm) [36]. 
3.2 Theory of Ultrasound Operation 
In the simplest sense, a beam of ultrasound energy (the frequency of which can 
vary depending upon the probe selected) is emitted from a probe at the surface of 
the skin, penetrates the skull and tissues and is reflected by moving blood cells back 
to the probe. Typically, a 2 MHz pulsed-wave (PW) probe is used to insonate vessels 
within the cranium. The 4 and 8 MHz continuous-wave (CW) probes may be used 
to insonate deep and superficial peripheral vessels, respectively, i.e., the common 
carotid (neck) and radial (forearm) arteries. The moving blood cells cause a shift in 
the frequency of the sound waves received by the detector in the probe. This shift in 
frequency is proportional to the velocity of the blood flowing through the vessel on 
which the beam is focussed [1]. This Doppler shift is given by the equation 
2fovcos0 
where A/ is the shifted frequency at the detector, fo is the emitted frequency at the 
source, v is the velocity of the moving blood cell, 9 is the angle between the probe 
and the velocity vector and c is the velocity of sound in tissue (usually taken to be 
approximately 1-540 mis). 
Figure 3.1 shows a typical velocity waveform from the middle cerebral artery in 
a /luman obtained during pilot work with the Medasonics Transpect TCD system. It 
is evident from the figure that the Doppler shift for blood flowing in arteries is not 
a pure frequency such as that from a single moving reflector. The signal received is 
a mixture of different frequency components coming from reflectors (i.e., blood cells 
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Figure 3.1: Typical velocity waveform from the human middle cerebral artery ob­
tained during pilot work with the Medasonics Transpect TCD system 
Figure 3.2: Typical velocity waveform from the canine middle cerebral artery 
(MCA) obtained during pilot work with the Medasonics Transpect TCD 
system 
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moving at different velocities. The spectral broadening effect is even more prominent 
in the transcranial approach than in cervical, peripheral or cardiac Doppler because 
the sample volume size is relatively larger compared to the dimensions of the arteries. 
Thus, not only is the entire cross-section of the lumen insonated, but branches, 
different segments of curves and nearby vessels all contribute to the Doppler signal 
received. 
3.2.1 Pulsed vs. continuous wave Doppler 
There are essentially two forms of Doppler ultrasound. They are known as pulsed 
wave (PW) Doppler and continuous wave (CVV) Doppler. 
3.2.1.1 Pulsed wave Doppler As mentioned above. TCD uses pulsed wave 
(PW) Doppler to measure blood flow velocity in the brain. In PW-Doppler. a sin­
gle crystal is used as the source and the receiver. Bursts of ultrasonic energy are 
transmitted at regular intervals with a burst- or pulse-repetition frequency (PFR). 
These bursts travel (at velocity c) toward the reflector which is separated from the 
transmitter by a distance L. Some energy is reflected and travels back at the same 
O f .  propagation velocity. Thus, at a time t = ^ after the emission of the burst, the 
reflected echoes come back to the transducer. The echoes are transformed into elec­
trical signals and amplified. The principle of range-gating is in practice realized by 
an electronic gate which opens and samples the signal for only a short period around 
the time t. Signals arriving from reflectors at different times and their effects are 
therefore eliminated from the sampled signal. 
In PW-Doppler, PFR decreases as depth increases and vice versa { P F R  x 
It has excellent range resolution by employing the idea of a sample vol­
ume. A sample volume is the volume in space from which the TCD signals are being 
obtained. As mentioned earlier, the sample volume is typically much larger than the 
diameter of the artery and thus encompasses not only the entire cross-section of the 
lumen insonated, but branches, different segments of curves and nearby vessels as 
well. The principal disadvantage of PW-Doppler is aliasing (Nyquist limit = }^PFR 
and PFR is limited by depth). 
3.2.1.2 Continuous wave Doppler In contrast to PW-Doppler, continu­
ous wave (CW) Doppler lises two crystals, one for the source and the other for the 
receiver. The source crystal emits a continuous sound wave which penetrates the 
tissues and is reflected back (same as the PW-Doppler case) to the receiver. In this 
fashion, information is obtained from the entire tissue slice in the line-of-sight of the 
transducer at all depths rather than from a particular depth as in PW-Doppler. The 
principal disadvantage of CW-Doppler is that it lacks range resolution but it does 
have an unlimited frequency response. 
3.3 Accuracy of TCD Measurements 
In recent studies, it has been shown that TCD does not provide an accurate 
measure of absolute BFV but can reliably detect relative changes in BFV i35j. The 
magnitude of these changes (as observed in humans) may be on the order of a few 
percent to several orders of magnitude. For example, in the middle cerebral artery 
(MCA), the BFV typically doubles during hyperventilation compared to at rest 341. 
In the presence of a unilateral stenosis in an internal carotid artery. BFV in the MCA 
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may decrease 10% for a moderate stenosis (75-89% occlusion) to 25%' or greater for 
a severe stenosis (90-99% occlusion) [24]. 
3.4 Probe Location 
The first step in a transcranial Doppler examination is to localize a cranial 
window that the ultrasound can penetrate without being excessively damped. There 
are three commonly used approaches in human medicine. They are: 
• Trans temporal approach to the basal cerebral arteries including the circle 
of Willis (see page 17). 
• Transorbital approach through the orbit of the eye to the carotid siphon. 
• Transoccipital approach through the foramen magnum near the base of the 
skull to the basilar artery and the intracranial segments of the vertebral arteries 
(see page 17). 
Perhaps the most commonly used point of insonation is the transtemporal approach 
where the probe is positioned over the temporal bone. From this position, several 
vessels including the MCLA., ICA and AC A can be well insonated (see Figures 2.4 and 
2.5). 
Using these three windows into the brain, any major cerebral vessel can be 
studied. Figure 3.2 shows a typical waveform from the middle cerebral artery via a 
transtemporal approach on a 72 lb. greyhound dog. Flow above the zero line indicates 
flow toward the probe while flow below the zero line indicates flow away from the 
probe. Note that the display indicates that the sample volume is at a depth of 6.2 
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cm. It is important to note that these are TCD centimeters and while this depth 
will likely be approximately equal to the actual depth, due to slight differences in c 
through the various tissue layers, it will not be exactly the same. The row of (white) 
back-lit boxes in the lower left corner of the display is the window-finder feature: the 
more boxes that are present, the more signal is getting through the bone.^ 
3.5 Artery Identification 
Once an adequate window is found and a blood flow velocity waveform is ob­
tained, the location of the signal {i.e., which vessel(s) is it coming from) must be 
determined. There are three main sources of information for artery identification. 
They are: 
1. The spatial relation of the signal to other intracranial signals including both 
the depth of the sample volume and the angle of the probe. 
2. The direction of flow (toward or away from the transducer) and the spectral 
distribution. 
3. The response of the signal to (common carotid) compression or vibration ma­
neuvers. 
These three pieces of information must be used in conjunction with one another 
to accurately determine the location of the signal (see section 4.4.4). One cannot 
positively identify the location of a TCD signal from simply looking at the picture. 
^The window-finder feature was not available on the EME TC2-64 used in this 
study. 
3.6 TCD in the Canine 
After its development by Aaslid in Germany, TCD has been commercially avail­
able in U.S. since 1986. The vast majority of TCD research has been in the human 
clinical areas of neurology, neurosurgery and anesthesiology. Despite its obvious ap­
plications in a variety of research areas (both animal and human). TCD has had 
extremely limited use in animal research. TCD has been successfully used in pigs 
to measure the effectiveness of cardiopulmonary resuscitation (CPR) in maintaining 
adequate cerebral blood flow. Rabbits and cats have been used by a handful of TCD 
researchers with limited success. To date, the only study using TCD in dogs was 
reported by Werner in 1990 [.35]. In this study, a portion of the skull was surgically 
removed and an 8 MHz ultrasound probe was placed directly on the dura mater to 
insonate various cerebral vessels. An extensive review of the literature revealed no 
published studies that employed TCD in toxicology or neurotoxicology. 
Although the pilot work demonstrated that CBF measures can be obtained from 
the dog (see page 33). there were some problems which had to be resolved before this 
new technology could be routinely applied in animal research. 
First, in human clinical applications, TCD is used to monitor CBF during pro­
cedures such as open-heart surgery and carotid endarterectomy where the probe 
placement is constant, or it may be used periodically over weeks or longer to fol­
low the progress of a disease such as atherosclerosis. In these circumstances, only 
changes in the shape of the velocity waveform are of interest. In this study, repeated 
CBF measurements were made on different days, thus it was important to insure 
that measurements were consistently taken from the same area of a particular vessel. 
Therefore, probe placement was of primary importance. For human clinical applica­
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tions, the probe is most often manipulated freely by hand to locate a target vessel, or 
the probe may be attached to a simple helmet to hold it in place. In the deltamethrin 
study, it was essential that probe placement be precise in 3-dimensional space. 
Another concern is that of probe stability. The area where the beam is focused 
within the cranium (called the sample volume) is quite small with respect to the vol­
ume of the brain (on the order of several mm^ ). Therefore, the anatomical location 
of the probe and the three-dimensional angle of incidence of the beam to the skull 
greatly affect the location of the sample volume. Thus, when using TCD. it is im­
portant to maintain a steady probe position to minimize noise and obtain accurate 
Waveforms. 
3.7 Summary of TCD 
To use TCD effectively, the user must have a good understanding of cerebral 
vascular anatomy (human and dog) and the relative position of vessels with respect 
to one another to properly locate and identify TCD waveforms. However, for the 
purposes of this project, only the blood flow changes in the middle cerebral artery 
(MCA) were of interest. The MCA was chosen because it is a relatively large artery 
which supplies much of the lateral surface of the cerebrum [21. In addition, it is 
usually easy to locate and obtain adequate signal quality using the TCD. 
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4. MATERIALS AND METHODS 
This project was completed in four phases. The description of each phase below 
essentially outlines the chronological sequence of events of the project. 
• Phase I: The goal of phase I was to answer the following initial questions: 
1. Could TCD be used to obtain blood flow velocity signals from various 
cerebral vessels within the brains of dogs? 
2. Was the signal-to-noise ratio of the blood flow velocity waveform large 
enough to provide adequate signal strength and integrity? 
3. Was TCD sensitive enough (in the dog) to detect changes in cerebral blood 
flow caused by breathing an increased concentration of COo? 
4. Which commercially available TCD instrument was best suited for use in 
this study? 
• Phase II: The goal of phase II was to carry out a dose-response pilot study to 
determine the appropriate deltamethrin dosages (low and high) to be used. 
• Phase III: The goal of phase III was to determine whether the system could 
detect changes in CBF in an unconscious (anaesthetized) dog. 
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• Phase IV: The goal of phase IV was to determine whether the system could 
detect changes in cerebral blood flow in a conscious (unanesthetized) dog. If 
so, any potential interaction between deltamethrin and the anaesthetic used in 
phase III could be eliminated. 
Each phase had its own problems to be overcome and questions to be resolved before 
the project could progress to the next phase. 
4.1 Experimental Design 
It has been well established that pyrethroids have a pronounced effect on rCBF in 
rats and other lower mammals (see section 2.3.3). As discussed earlier, deltamethrin 
increased rC'BF in 14 areas of the brain studied in rats by the microsphere technique 
(see section 2.3.3). Based on these findings, the null hypothesis of this study was: 
Deltamethrin at 5 and 10% of the LD^q administered intravenously will not alter the 
blood flow velocity in the middle cerebral artery of the dog. 
4.1.1 Justification of animal use 
.4s is the case with most experiments in toxicology, it is not appropriate to 
purposely expose human subjects to potentially harmful toxic substances: therefore, 
an animal model was used to study the effects of toxicants on CBF. The greyhound 
dog was chosen as the animal model for this study for the following reasons: 
• While there are some differences, the anatomy of the canine cerebral circulation 
is similar to that of humans, 
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• Dogs possess a large enough circle of Willis (see page IT) (compared with rats, 
for example) to allow TCD to distinguish signals from the various vessels within 
the cranium, 
• The amount of extracranial muscle and soft tissue {i.e., the distance between 
the skull and skin surface) is relatively small compared to other breeds and is 
the most similar to the human for the transtemporal approach, 
• The greyhound has a relatively thin skull (1.4 mm thick^) compared to the 
human (1.2-2.5 mm thick [1]) and therefore it should produce less attenuation 
of the transmitted and reflected signals [36], 
• The greyhound is a domesticated subject and easy to work with, 
• The greyhound racing industry is economically important in this state and dogs 
are readily available. 
Unfortunately, greyhounds were more difficult to obtain than had originally been 
anticipated: therefore, it was necessary to use three large mongrel dogs in addition 
to the nine greyhounds to complete Phase III of this study. 
4.2 Phase I - Evaluation of TCD Equipment 
During Phase I of the project, several TCD instruments were brought into the 
laboratory for on-site evaluation and testing. The most promising instruments were 
the Transpect TCD from Medasonics ( Mountainview. CA) and the TC2-64B from 
^Skull thickness measured in our laboratory of the temporal bone on a skull of a 
greyhound dog of comparable weight to those used in this study, at a point close to 
that used in the transtemporal approach. 
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Eden Medical Electronics (Kent. WA). In addition, the GenesisII from Biosound 
(Indianapolis, IN) was tried on a dog but was unsatisfactory due to a lack of signal 
strength. Further, the 500V from Multigon (Mt. Vernon, NY) was considered and 
rejected because of excessive cost. Since TCD is a relatively new technique and 
has not been used in dogs, both Medasonics and EME were willing to make their 
instruments available for a one month evaluation period. In both cases, 2 MHz probes 
were used to insonate the middle cerebral artery as well as several distinct bifurcations 
around the circle of Willis (transtemporal approach). COg was introduced into the 
respired air and a distinct increase in CBF was detected. Both systems provide similar 
features with the following-exception: the Transpect TCD has a window finder that 
indicates how much of the ultrasound signal is actually getting through the bone. 
Since no database of TCD usage in dogs existed at the time of the study, this feature 
was initially believed to be particularly useful in locating target arteries. Although 
exploratory work with transcranial Doppler sonography in dogs had just begun, this 
researcher was confident that CBF changes could be measured from several locations 
in the cerebral circulatory system and that responses to manipulations of CBF could 
be detected using TCD. 
With substantial practice, it was determined that TCD could be adequately used 
in dogs and that changes in CBF caused by manipulation of CO ) could be observed 
(data to support this observation was not recorded because there was no computer 
interface nor video printer available during Phase I). It was decided that because the 
EME TC2-64 supplied an (undocumented) analog voltage on a pin in the rear of the 
unit which corresponded to the mean envelope velocity of the BFV waveform (see 
page 47), the TC2-64 would be used rather than the Medasonics Transpect TCD 
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which did not provide this feature (or any other convenient way to store continuous 
BFV waveform data on a PC). 
4.3 Phase II - Dose-Response Pilot Study 
According to the National Institute for Occupational Safety and Health (NIOSH) 
Registry for Toxic Effects of Chemical Substances (RTECS) January, 1991 edition, 
the intravenous LDgg for deltamethrin in dogs is 3.44 ± 0.67mg!kg. RTECS cites 
Chanh [6] as the source for this data. The protocol used by Chanh was as follows: 
The dogs employed were mongrels of both sexes weighing 10-15 kg. anaes­
thetized with pentobarbital (Nembutal, 25 mg/kg i.v.). Deltamethrin was 
dissolved in glycerol formal (50 mg/ml) and less than 1 ml injected in­
travenously via the saphenous vein, or suspended in gum-arabic solution 
and administered by means of a duodenal cannula. In both cases, del­
tamethrin was given in a single dose and the treated animals were kept 
under observation for 5 hours after administration of the drug. The LD^q 
values were calculated by the probit method, (page 127). 
Using this as a starting point, various levels of exposure (each less than 10% of the 
LD5Q ) were tested. 
.4.s discussed earlier, based on previous experiments using rats, it was expected 
that deltamethrin would increase CBF (see page 13). In general, barbiturates, (i.e.. 
pentobarbital) are potent cerebral vasoconstrictors which elicit characteristic dose-
related and potentially large decreases in CBF (see page 5). However, it is very 
difficult to maintain a constant level of anaesthesia using an injectable anaesthetic 
such as pentobarbital. Therefore, halothane (a gas anaesthetic) was used to maintain 
a more constant level of anesthesia. .A.s discussed previously (see page 5). halothane 
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Table 4.1: Amount of deltaniethrin administered to each dog for each exposure 
(N/A denotes where an animal has been removed from the study) 
Dog Mass of Dog Mass of Deltamethrin (mg) 
Number (kg) 5% LD^n 10% LD50 
1 26.0 4.5 8.9 
2 .30.0 5.2 10.3 
3 32.0 5.5 11.1 
4 23.0 4.0 7.9 
5 29.5 5.1 N/A. 
6 33.0 5.7 11.4 
7 .32.0 5.5 11.1 
8 33.0 5.6 11.4 
9 31.0 5.3 10.7 
10 .38.0 6.5 13.1 
11 29.0 4.9 N / A  
12 27.5 4.7 9.5 
acts to increase cerebral blood flow ( i CBF). Thus, both deltamethrin and halothane 
confound interpretations of data because both substances act to increase CBF. 
Each animal was exposed to two levels of deltamethrin 48 hours apart. A low 
level {5% of the LD.^Q) and a high level ( 10% of the LD^Q) of deltamethrin were used. 
Technical grade (>98% purity) deltamethrin (Hoechst Chemical Co.. Saskatchewan. 
Canada) was dissolved into glycerol-formal (Sigma Chemical Co.. St. Louis. MO. 
#Gl.513) in concentrations of o, 10, and 15 mg/ml. The volume of solution for each 
injection was held constant at 1 ml. Based on the weight of the animal, the amount 
of deltamethrin was calculated, withdrawn from the appropriate mixture into a 1-ml 
tuberculin syringe and diluted with pure glycerol-formal to make exactly 1 ml. 
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4.4 Phase III - Deltamethrin Exposure in the Unconscious Dog 
These experiments were performed after approval of the Institutional Animal 
Use Committee. Deltamethrin was administered to 12 dogs weighing 30.3 ±3.Skg (9 
greyhounds and 3 mongrels) of both sexes. It was given at two relatively low dosage 
levels, approximately 48 hours apart (see Table 4.3). Five physiological parameters 
were recorded during the control, glycerol-formal (no deltamethrin) and exposure 
(deltamethrin in glycerol-formal) periods. These parameters were mean blood flow 
velocity (MBFV) in the middle cerebral artery, mean arterial- blood pressure (MAP) 
in the aorta, end tidal COg, mean heart rate (MHR) and concentration of deltame­
thrin in the blood. 
4.4.1 Blood pressure measurement 
Approximately two to three days prior the first deltamethrin exposure, each 
dog had arterial and venous cannulas surgically implanted to facilitate direct arterial 
blood pressure measurements and to provide a consistent method for administering 
the deltamethrin and obtaining blood samples [29]. A cannula was inserted into the 
carotid artery contralateral to the side where TCD measurements were to be recorded. 
This minimized flow disturbances introduced by the presence of the cannula." The 
arterial cannula tip was located in the aorta (or sometimes in the carotid) to record 
arterial pressure, and the venous cannula tip was located in the jugular vein (verifi­
cat ion of  t ip placement was done post  mortem).  
"The cannula in the contralateral carotid artery should not alter CBF to any 
significant degree ipsilateral to the TCD probe due to the tremendous collateral 
circulation in the dog. 
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The construction and implantation of the cannulas are briefly described in the 
following two sections and described in greater detail in Appendices A and B. 
4.4.2 Cannula preparation 
Arterial and venous cannulas were obtained from Braintree Scientific. Inc.. ( Brain-
tree, MA, model numbers RPC-080-18 and MRP- 080-18, respectively). Prior to 
implantation, the distal end of each cannula had a 2-way stopcock cemented to the 
hub end and a Dacron patch was sutured around the cannulas and secured in place 
using Silastic cement. This patch was to allow for secure attachment to the skin. 
A short piece of silastic tubing (0.889mm I.D.. 0.254mm wall thickness) was soaked 
in xylene for approximately one minute to expand the silastic and then placed over 
the proximal tip of the venous catheter. The xylene evaporates in a few minutes 
and leaves a tight (shrink) fit of the silastic on the cannula. This flexible tip on the 
venous cannula decreased the possibility of a blood clot forming in the lumen of the 
cannula and of the cannula tip causing damage to the intimai tissues. The silastic tip 
was not placed over the arterial cannula because it would impede high fidelity blood 
pressure recordings. After sufficient curing (several days), each cannula was washed 
in a dilute Ivory soap flake solution to remove oils and other debris from the cannula, 
rinsed several times in sterile water and dried. Finally, the lumenal surface of each 
catheter was coated with a highly concentrated heparin solution (Braintree Scientific. 
TDMAC-Heparin) to form a non-thrombogenic plastic surface. The cannulas were 
individually packaged and gas-sterilized using ethylene oxide (see .Appendix .A.). 
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4.4.3 Cannula implantation 
Under general anaesthesia (halothane) and sterile conditions, a five to seven 
centimeter midline incision was made on the ventral aspect of the neck. Another 
incision, approximately three to five centimeters in length, was made on the dorsal 
aspect of the neck just cranial to the level of,the scapula. A stainless steel tube was 
inserted into the dorsal incision and run subcutaneously, exiting through the ventral 
incision. The distal ends of the cannulas were passed through the lumen of the tube 
from the dorsal to the ventral incision. The tube was removed leaving the cannulas 
in place. The skin of the dorsal incision was sutured to the Dacron patches and the 
incision was closed leaving the stopcocks exposed. The arterial cannula was inserted 
into the right carotid artery with the tip positioned at approximately the level of.the 
aorta (verification of tip placement was done post mortem). The venous cannula was 
inserted into the right jugular vein. Both cannulas were secured to the vessel wall 
using a purse-string suture in such a fashion as to leave the vessel patent. Finally, 
the cannulas were secured to the surrounding muscle and connective tissue and the 
incision was closed. The cannulas were flushed daily with heparinized saline (see 
.Appendix B). 
4.4.4 Experimental procedure 
The experimental procedure is outlined as follows: Each dog was anaesthetized 
using a mixture of Ketamine and Diazepam (equal volumes at 1 ml per 20 pounds), 
intubated, given halothane (approximately 1..5% as needed) and placed on a heated 
table in left lateral recumbency. A COo analyzer (Datex Instrumentation Corp., Fin­
land) was calibrated and attached to the endotracheal tube to monitor end-tidal COo. 
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A Statham P23Db pressure transducer was filled with saline (ensuring no air bubbles 
were present) and attached to the arterial cannula stopcock. The pressure transducer 
was attached to a Grass Model 7 Polygraph (Grass Instruments, Inc., Quincy. MA) 
that was in turn attached to a data acquisition system (Dataq Instruments. Inc., 
Model DI-420) connected to a Zenith 286 personal computer. 
A 2MHz pulsed-wave transcranial Doppler (TCD) probe (Eden Medical Elec­
tronics, Santa Clara, OA, Model TC2-64) was used in a transtemporal approach to 
insonate a portion of the left middle cerebral artery (see Figure 4.1). Verification 
of the MCA signal was accomplished by using signals from other cerebral vessels as 
relative landmarks in addition to observing the direction and magnitude of blood 
flow, depth of the sample volume and overall shape of the blood How velocity wave­
form. The TCD was used to locate and identify signals from a point on the middle 
cerebral artery (MC.A.) via transtemporal approach just downstream of the bifurca­
tion with the circle of Willis. The MC.A. supplies most of the lateral surface of the 
cerebrum. This point was chosen because of its ease of location with the TCD and 
i ts  close proximity to the MCA/IC.A. bifurcat ion which has a  characteris t ic  butterf ly  
waveform. The BFV waveform spectrum from the TCD was stored on video tape 
while the maximum frequency follower (envelope velocity) signal was stored in the 
PC. 
An Amiga 1000 personal computer and A1300 genlock (Commodore Business 
Machines, Westchester, P.A) were used to superimpose text information on the video 
tape to identify different experimental conditions for post-experimental viewing. Fi­
nally, a video printer (Sony, Model UP-80O) was attached to the TCD to allow peri­
odic hardcopy recordings of the TCD signal. 
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After all the equipment was in place and functioning properly, thirty minutes of 
control recording were obtained. Next, 1 ml of pure glycerol-formal was injected into 
the venous cannula and another 30 minutes of data was recorded. Finally, either the 
low- or high-level dosage of deltamethrin (according to the randomization schedule in 
Table 4.2), dissolved in glycerol-formal, was injected into the venous cannula and an 
additional 30 minutes of data was collected. Arterial blood pressure and MCA blood 
flow velocity were recorded continuously for the entire 90 minute period (sampling 
frequency of 50 Hz per channel). End tidal COg was recorded once every one to five 
minutes. Following the end of the 90 minute period, the dog was taken off anaesthesia 
and allowed to recover. This procedure was repeated two to three days later using 
the second dosage of deltamethrin. 
Venous blood samples (approximately 3-5 mis) were obtained from 4 dogs via 
the venous catheter during both the low- and high-level exposure periods at 0, 5. 
10, 15 and 30 minutes post exposure. These samples were analyzed by gas-liquid 
chromatography to determine the concentration of deltamethrin circulating in the 
blood [331. 
4.5 Phase IV - Deltamethrin Exposure in the Conscious Dog 
The final phase of this project involved administering deltamethrin and collecting 
data in a conscious (unanesthetized) dog. This would have a distinct advantage over 
Phase III because it would eliminate the possibility of an interaction between the del­
tamethrin and the anaesthetic. In addition, as previously mentioned, halothane and 
deltamethrin both tend to increase C'BF. It would certainly be possible for the effects 
of anaesthesia to mask the effects of the deltamethrin. Eliminating the anaesthesia 
Figure 4.1: Photograph showing experimental setup in Phase III 
igure 4.2: Photograph showing experimental setup in Phase IV 
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would eliminate the possibility of any masking of effects as well. 
Since TCD is very sensitive to movement, the animal (while still conscious) must 
be restrained. This was accomplished by placing the dogs in a canvas sling device to 
suspend the body and head. A helmet apparatus was used to establish a fixed point 
of reference (see Figure 4.2). The TCD probe was securely attached to the helmet 
while still allowing 6 degrees-of-freedom to move the probe to obtain the desired 
signal. The 3-Space Isotrak system^ was used to determine exact probe placement 
so that repeated measurements could be reliably taken using a single probe. The 
2 MHz TCD probe was attached to the Isotrak probe detector via a plexiglass tube 
to eliminate electromagnetic noise generated by the TCD. Unfortunately, no data was 
collected for any animals during Phase IV because, while the animals were conditioned 
to the sling, it was imposible to keep the head still enough to verify, the location of 
a signal after it had been found. Consequently, all data presented in the remaining 
chapters was from Phases II and III. 
4.6 Statistical Methods 
For this experiment, each animal was subjected to three procedures. On day 1. 
the chronic arterial and venous cannulas were surgically implanted. On day 3. the 
first exposure to deltamethrin was carried out. Finally, on day 5, the second exposure 
to deltamethrin was completed. Following the second exposure, the animal was 
either used for another terminal experiment or euthanized and used in the Veterinary 
.\natomy teaching laboratory. 
•^Polhemus, Inc., Colchester, VT. (802) 655-3159. 
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4.6.1 Statistical design 
All experiments consisted of three consecutive periods of 30 minutes each. Heart 
rate, arterial blood pressure and blood flow velocity were recorded continuously dur­
ing each 30 minute period. End tidal CO2 was recorded once every 5 minutes during 
each period. The first period was the control. Following the control period, 1 ml of 
glycerol-formal solution (no deltamethrin) was administered and data was recorded 
for 30 minutes. Finally, deltamethrin (in glycerol-formal) was administered (expo­
sure period) and data was collected for an additional 30 minutes. Thus, for each dog. 
there were 3 periods per experiment and 2 experiments per dog (low and high) for a 
total of 180 minutes of continuous data collected. 
A randomization table was used to determine the deltamethrin exposure sched­
ule. In this design, two sources of variability were controlled. In this case, these 
nuisance variables were: 
• cumulative interactive effects — one deltamethrin exposure that may in­
teract with a future deltamethrin exposure in the same animal at a later time. 
• multiple animal subjects — not all animals react exactly the same to the 
same level of exposure. 
Three levels of exposure were used: a baseline level (b)  which is solvent alone (no 
deltamethrin), a low-level (/) and a high-level (h) exposure. The low-level exposure 
was the level at which CBF changes were first observed and further C'BF changes 
were anticipated at the high-level exposure. 
Table 4.2 shows one replication of the exposure schedule which was used. Two 
replications (n = 12) were used to minimize standard error. Note that in Table 4.2. 
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Table 4.2: Randomization schedule (one replication). b=baseline (no deltamethrin). 
1=low-level dosage, h=high-level dosage 
Dog 
Exposure 1 2 3 4 5 6 I 
. 1 b b b b b b 
h 1 h h 1 1 
2 . b b b b b b 
1 h 1 1 h h 
the first exposure in each cell is always b.  a baseline measurement, followed by either 
a low- or high-level exposure. This insured that there were no cumulative effects 
within any given cell (i.e., I immediately followed by h within the same cell). 
4.6.2 Statistical analysis 
Each measured physiological parameter ( i .e . ,  MAP. MHR, MBFV and pCOo) 
and each calculated parameter (i.e., SDR, GPI, PPI and upstroke) were calculated 
for each minute during each period. The control, glycerol-formal and deltamethrin 
periods were divided into three blocks (1-10 minutes, 11-20 minutes and 21-30 min­
utes). These period-blocks were denoted C'2, C'g, Co. and Do. Dg. 
respectively. A randomized block factorial design and a Tu key studentized range test 
were used to test for significant differences between period-blocks. 
In a randomized block factorial design (RBF-pg), the fixed-effects linear model 
is: 
^i jm — / '  + ~i jm'  
where /( is the grand mean of the treatment populations, ay is the effect of treatment 
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i  which is constant for all subjects within the treatment population i .  3 j  is the effect 
of treatment which is constant for all subjects within the treatment population j, 
is the effect which represents the nonadditivity of effects aj and 3j, ~m is a 
constant associated with block m, and ^ijm is the experimental error : 18]. 
For this experiment, there are three periods [p = 3) and three blocks (q  = 3) 
within each period. Thus, an analysis of variance is preformed using a RBF-33 design. 
Finally, Tukey's test declares two means significantly different if the absolute value 
of their sample differences exceeds a minimum significant difference (MSD) used for 
all comparisons[23j. In other words, if 
where ifj and are period-block means (for example, C'l and D]^). and MSD is 
the minimum significant difference, then there is sufficient evidence to reject the null 
hypothesis and conclude that C'l and D-^ are significantly different. 
'^Unless otherwise indicated, all period-block mean comparisons were made using 
the Tukey test. 
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5. RESULTS 
Figure 5.1 shows a typical TCD recording from a canine middle cerebral artery. 
This example shows that the blood flow velocity measured by the TCD is not a simple 
waveform but a spectrum of points representing a range of blood flow velocities for a 
given point in time. The TCD provides a voltage proportional to the maximum fre­
quency follower (or envelope) velocity which is the maximum frequency (or velocity) 
at a given point in time. This velocity waveform was digitized and stored in the PC. 
However, due to the nature of the maximum frequency follower, the signal tends to 
be very noisy as evidenced by the example raw blood flow velocity waveform shown 
in Figure 5.2. Thus, some form of signal conditioning or filtering must be applied to 
be able to extract any useful data. 
5.1 Conditioning BFV Data 
Changes in CBF resulting from exposure to deltamethrin or other pyrethroids 
are very subtle and occur over several minutes. At low exposure levels, no beat-to-
beat changes were expected. Therefore, the following algorithm (see Appendix D. 
page 94) was implemented to condition and condense the BFV data: First, the data 
was separated into one minute intervals. Due to the noisiness of the BFV signal, 
it was difficult to define each individual heart beat using the BFV waveform alone. 
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Figure 5.1: Typical TCD recording obtained from the MCA of a Z2kg Greyhound 
dog; vertical scale is velocity (cm/sec), horizontal scale is time (sec), 
data above the zero line is flow toward the probe, below the zero line is 
flow away from the probe; depth of sample volume is displayed in upper 
right 
10 seconds 
10 minutes 
Figure 5.2: Top: Original BFV waveform (from maximum frequency follower of 
TCD); Bottom: Conditioned BFV waveform 
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Therefore, the minimum points on the blood pressure waveform (diastolic pressures) 
were used to define each heart cycle. These points were determined using the peak 
and valley detection algorithm in the Codas software package^. Each minute of BFV 
data was then divided into individual heart cycles using the definition just described. 
The number of samples within each heart cycle is summed and the mean and standard 
deviation is calculated. Then, any heart cycle containing a total number of observa­
tions outside the range of the mean plus or minus one standard deviation (J ± 1er) is 
discarded. Finally, the first observations for each heart cycle are averaged, followed 
by the second observations, and so on over the minute of data. The averaged points 
are put back together to form an average or composite BFV waveform representa­
tive of that particular minute of data. By eliminating those waveforms containing 
a total number of samples outside the x ± la range, the possibility of phase shifts 
occurring in the averaging and reconstruction is greatly reduced. This scheme had 
the secondary benefit of automatically discarding any section of data in which a can­
nula was flushed because the number of samples was significantly different from the 
normal heart cycles and thus was rejected. 
The justification for using this type of signal conditioning is twofold: First, subtle 
changes occurring over several minutes and not beat-to-beat changes were expected. 
.A.nd second, the heart rate remained relatively constant over the one minute interval. 
If either of these conditions were false, then the method described above would not be 
appropriate for this analysis. In using this method, a much cleaner velocity signal was 
obtained (Figure 5.2), but at the expense of a significant amount of data. For a given 
^Dataq Instruments, Inc.. 150 Springside Drive, Suite B'220, .Akron. OH 44333. 
216-668-1444. 
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minute of data, initially perhaps 100 heart cycles (depending on heart rate) were 
present, and after conditioning, one heart cycle representative of the entire minute 
was obtained. 
5.2 Physiological and Calculated Parameters 
After obtaining a clean signal, mean arterial pressure (MAP), mean heart rate 
(MHR), mean blood flow velocity (MBFV) and end tidal CO2 (PCO2) in the con­
trol, glycerol-formal (solvent) and deltamethrin periods were compared. Additionally, 
there were four parameters that were obtained from the BFV waveform that are typ­
ically of clinical interest. They are: 
1. Systolic to Diastolic Ratio (SDR) 
V'J 
SDR = -A 
2. Pourcelout Pulsatility Index (PPI) 
' . 4  
.3. Gosling Pulsatility Index (GPI) 
V'J - V GPI = '-AZM 
V 
4. Average Systolic Upstroke (SU) 
c;rr  ' ,  
where V is blood flow velocity at points A and B (maximum systolic and minimum 
diastolic locations, respectively) as show in Figure 5.3. 
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Figure 5.3: Calculated parameters from the BFV waveform 
5.3 Results of Dose-Response Pilot Study 
Two greyhound dogs were used in a pilot study to determine the low- and high-
level deltamethrin exposure levels. It was hoped that the low-level exposure would 
correspond to a level where some changes might be detected and the high-level ex­
posure would correspond to a level where some changes would be detected. No dogs 
were exposed to greater than 10% of the LD5Q because this would certainly be more 
than most individuals would be exposed to in the home or at the workplace. 
Figure 5.4 (top) shows the results of a 7.5% LD^q exposure immediately followed 
by a 10% LD5Q exposure on a 30&# female Greyhound. After each exposure, a 
slight increase in MAP, a distinct decrease in MHR and increase in pCOg, and a 
defini te  increase in MBFV last ing approximately 10 to 15 minutes j )ost  exposure 
were observed. Figure 5.4 (bottom) shows the various BFV waveform parameters 
described previously. None of the four calculated parameters shown seems to indicate 
any observable changes that may be an indicator of exposure. 
Based on the results of the pilot study, it was decided that the low- and high-
level exposure levels would be set at 5% and 10% of the LD^g value, respectively. 
These levels meet all of the exposure criteria mentioned previously. 
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Figure 5.4: Two exposures of deltamethrin (7.5% LDgQ immediately followed by a 
10% LD50) in & 30&g Greyhound; upper graph shows measured physi­
ological parameters; lower graph shows calculated parameters from the 
BFV waveform 
5.4 Concentration of Deltamethrin in Blood 
The concentration of deltamethrin in the blood as a function of time post  exposure 
is shown in Figure 5.5. Notice that at i = 0 (just before injection of deltamethrin), 
there is no deltamethrin present in the blood. • This indicates that waiting 24-48 
hours between exposures was an adequate amount of time for the deltamethrin to 
be cleared from the circulation after a previous exposure. Of course, it is certainly 
possibly that some deltamethrin was stored in adipose or other tissues and would not 
be present in the blood. Further, it is possible that some unnoticeable permanent 
alterations may be present that may bias the results from the second exposure. There 
was no indication that this occurred, and the randomization scheme described earlier 
should control for this possibility. 
Although there is a limited amount of data available in Figure 5.5 on page 54 
(n = 4 for each exposure), during both exposure levels, the concentration curves 
exhibit the characteristic rise and exponential decay ((/ = ae~^^ ) expected after the 
injection of any substance that is slowly removed from the circulation. Deltamethrin 
is metabolized in the liver [-3]. However, perhaps some is absorbed into the CNS 
and/or stored in adipose or other tissue. It is even possible that some may dissociate 
when exposed to blood. 
5.5 Typical Results 
Unfortunately, not all of the data obtained in these experiments exhibit the 
magnitude of responses shown in Figure 5.4 (top). Figures 5.6 ancl 5.7 show the results 
from low- and high-level deltamethrin exposures, respectively, done three days apart 
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Figure 5.5: Concentration of deltamethrin in blood at 0, 5, 10, 15 and 30 min­
utes post  exposure]  circles indicate low-level  (5% LDgg exposure (n=4)]  
squares indicate high-level ( 10% LD50 exposure {n=4)\ range represents 
standard error 
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in a Z' lkg male Greyhound. Similar changes were observed in MAP, MHR. C'Oo and 
MBFV but to a much lesser degree compared to Figure 5.4. Again. Figures 5.6 and 
5.7 show no consistent changes in calculated waveform parameters with the possible 
exception of some minor increases in pulsatility immediately following exposure. 
5.6 Results of Physiological Parameters 
In Phase III of this study (exposure to unconscious dogs), a total of 12 dogs 
weighing 30.3 ± 3.8% (9 greyhounds and 3 mongrels) were subjected to the low-
level deltamethrin exposure. Two of the dogs that were subjected to the low-level 
exposure first developed complications which were unrelated to this study. Both dogs 
were removed leaving 10 dogs for the high-level exposure. An analysis of variance 
was carried out for each of the physiological and calculated parameters comparing 
the 9 period-blocks (treatment x time) according to the procedure outlined in Section 
4.6.2 (page 45). 
Tables 5.1 and 5.2 summarize the period-block means for the measured and 
calculated parameters. In these tables. C'x is control period at time block .r. G'.r 
is glycerol-formal period at time block x, Dx is deltamethrin period at time block 
.r, MSE is mean square error, CV is critical value of studentized range and MSD 
is minimum significant difference. In addition, the letters below each mean denote 
which means were not significantly different, i.e., means with an .4 in a given column 
do not significantly differ, but one mean with an .4 and another mean with a B do 
significantly differ. These letters should be considered individually, in other words, 
the grouping ABC has no significance. For certain parameters (MHR. SDR and SU), 
the Tu key test does not detect significant differences between period-blocks when by 
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Figure 5.6: Control, solvent (glycerol-formal) and low level deitamethrin exposure 
(5% LD_5q) in a 3'2kg greyhound; upper graph shows measured physi­
ological parameters; lower graph shows calculated parameters from the 
BFV waveform 
•57 
MAP (mmHg), MHR (bpm), MBFV (cm/s) End Tidal C02 (%) 
Control 
MAP 
WW/? 
Glycerol-Formal Deltamethrin 
MBFV 
pC02 
1 t 1 1 1 1 
12 
11 
10 
9 
8 
CI C2 C3 G1 
S/D Ratio, PPI, GPI (%) 
G2 G3 D1 D2 D3 
Upstroke (cm/s/s) 
1.5 
0.5 
SDR 
GP/ A A 
1 A 
1 1 
1 
¥ 
6 
5 
200 
150 
100 
50 
0 10 20 30 40 50 60 70 80 90 
Time, minutes 
Figure 5.7: Control, solvent (glycerol-formal) and high level deltainethrin exposure 
(10% LD50 in a Z2kg greyhound; upper graph shows measured physi­
ological parameters; lower graph shows calculated parameters from the 
BFV waveform 
Table 5.1: Period-block means for low-level exposure (h = 12,a = 0.05,<// = 88), 
see text for further explanation 
Mean Systolic 
Mean Mean End Blood to Pourcelout Colsing 
Period Arterial Heart Tidal Flow Diastolic Pulsatiltiy Pulsatiltiy Systolic 
Block Pressure Rate CO, Velocity Ratio Index Index Upstroke 
{ininHg) {bp in)  (%) {cm/s)  (%) (%) {cni /s-)  
C'L 91.9 116.7 6.8 33.2 2.61 0.40 0.59 29.07 
(A) (ab- -) (- -C) (- -C) (a-) (A--) (A-) (-b) 
C2 92.5 122.3 6.9 34.6 1.93 0.37 0.54 50.85 
( A )  (a- - -) (-BC) ( B C )  (ab) (ABC) ( A B )  (ab) 
^ '3  92.5 120.8 7.1 35.8 1.66 0.35 0.48 50.82 
(A) (ab- -) ( - B C )  (ABC) (ab) (ABC) (AB) (ab) 
94.3 118.7 7.1 37.4 1.54 0.33 0.44 32.22 
( A )  (ab- -) ( B C )  (AB.) (-b) ( B C )  (-B) (-b) 
cu 95.0 116.4 7.3 37.9 1.51 0.32 0.41 41.97 
( A )  (ab- -) (-B-) (A--) (-b) (- -C) (-B) (ab) 
G3 95.1 113.5 7.2 36.8 1.61 0.33 0.43 39.86 
(A) (-be-) (-BC) ( A B . )  (ab) (-BC) (-B) (ab) 
D, 92.5 102.3 7.9 37.7 1.68 0.36 0.51 47.95 
(A) ( - - - d )  (A--) (A--) (ab) (ABC) (AB) (ab) 
Do 92.3 102.8 7.9 36.1 1.66 0.37 0.51 61.37 
(A) ( - - - d )  (A--) ( A B C )  (ab) (AB-) (AB) (a-) 
D, 90.3 106.5 7.9 35.4 1.66 0.37 0.51 47.22 
(A) (- - cd) (A- -) ( A B C )  (ab) (ABC) (AB) (ab) 
MSE 72.6 80.7 0.1 4.9 1.19 O.Ol 0.01 567.32 
CV 4.4 (4.4) 4.4 4.4 (4.49) 4.49 4.49 (4.49) 
MSD 11.0 (11.6) 0.44 2.89 (1.41) 0.05 0.14 (30.92) 
Table 5.2: Period-block means for high-level exposure (?i = 10, a = 0.05, r// = 72), 
see text for further explanation 
Mean Systolic 
Mean Mean End Blood to Pourcelout Golsing 
Period Arterial Heart Tidal Flow Diastolic Pulsatiltiy Pulsatiltiy Systolic 
Block Pressure Rate rOz Velocity Ratio Index Index Upstroke 
{mmHg) {bpm) (%)  {cm/s)  (%)  (%)  {cm/s-)  
84.4 118.4 7 .5 25.7 1.68 0.38 0.53 26.26 
(- -c) (a-) . (-B) (- -c) (a- -) ( A - - : - )  (A ) (-be) 
^•2 88.7 117.8 7.3 27.2 1.62 0.35 0.49 24.27 
(-BC) (a-) (-B) (ABC) (a- -) (AB- - -) (AB- -) (-be) 
Oz 89.9 118.9 7.4 28.3 1.55 0.33 0.44 26.0 
(-BC) (a-) (-B) (ABC) (ah- -) (-BC- -) ( A B C )  (-be) 
G, 92.9 117.1 7.5 30.1 1.47 0.30 0.39 22.1 
(ABC) (a-) (-B) (ABC) (-be-) (- -CDE) (-BCD) (- -c) 
G2 9G.1 118.5 7.6 30.G 1.41 0.27 0.35 26.55 
( A B )  (a-) (-B) (AB-) (- -C-) (- - -DE) ( -  - C D )  (-be) 
O3 97.0 120.3 7.7 30.8 1.38 0.27 0.33 32.56 
( A B . )  (a-) (-B) ( A B . )  (- -C-)  ( E) ( - - - D )  (abc) 
D, 100.5 103.2 8.5 31.0 1.64 0.32 0.43 50.69 
( A - - )  (-b) ( A )  ( A - - )  (a ) ( B C D )  ( B C D )  (a- -) 
D2 9G.0 104.4 8.4 27.2 1.61 0.35 0.48 50.46 
(AB.) (-b) (A-) (ABC) (a ) (AB- - -) ( A B - - )  (a- -) 
Ds 92.7 108.5 8.4 26.3 1.60 0.35 0.48 44.58 
(ABC) (ab) ( A )  (-BC) (a ) (ABC- -) (AB- -) (ah-) 
M SE 42.2 114.4 0.2 9.9 0.01 0.00 0.00 459.48 
CV 4.5 (4.5) 4.5 4.5 (4.52) 4.52 4.52 ' (4.52) 
MSD 9.2 (17.1) 0.6 4.5 (0.18) 0.05 0.10 (30.65) 
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observation, they would be expected. For example, in the high-level MHR experiment 
(Figure 5.9 bottom), the Tukey test showed no significant difference between C'l and 
Di due to the large over-lapping standard errors between these two period-blocks. 
Thus, Duncan's multiple range test was used to compare these means. This is a 
slightly less conservative test then Tukey's test, but it is justified because it is very 
effective at detecting differences between means when real differences exist '2.31. In 
order to make fair comparrisons, howo.er, the same test (either Tukey's or Duncan's) 
is used for both the low- and high-level experiments for any given parameter. For 
instance, Tukey's test is used for MAP in both experiments while Duncan's test is 
used for MHR in both experiments. In tables 5.1 and 5.2, means coded with capital 
letters [ABC] were compared using Tukey's studentized range test while those means 
coded with, lowercase letters [abc) were compared using Duncan's multiple range 
test. For any given parameter, any two period-block means differ significantly if the 
a b s o l u t e  v a l u e  o f  t h e i r  d i f f e r e n c e  e x c e e d s  t h e  m i n i m u m  s i g n i f i c a n t  d i f f e r e n c e  ( M S D )  
for that parameter. The results of this analysis are discussed below. 
5.6.1 Mean arterial pressure 
.A, plot of mean arterial pressure (MAP) versus time is shown in Figure 5.8 (see 
page 62). The upper graph (circles) represents the low-level exposure and the lower 
graph (squares) represents the high-level exposure. MAP remains fairly constant 
throughout the low-level exposure experiment, and there were no statistically signif­
icant differences between any periods or any time blocks. 
For the high-level experiment, MAP tends to slightly increase through the control 
and glycerol-formal periods although these increases are not statistically significant. 
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There was a statistically significant difference between and (a = 0.05. M S D  =  
9.2) indicating that the 10% LDgg exposure was causing a significant increase (19%) 
in MAP within the first 10 minutes post exposure. Do and Dg do not significantly 
differ from C'2, C'3, G']_, Ct2 or G'3 (B grouping for MAP column in Table 5.2) indi­
cating that MAP returned to control levels after 10 minutes post exposure. Further, 
Dg does not significantly differ from , C'2, C'g and Gi indicating that MAP has 
returned to i ts  s tar t ing level  af ter  30 minutes post  exposure.  
5.6.2 Mean heart rate 
A plot of mean heart rate (MHR) versus time is shown in Figure 5.9 (see page 
64). The upper graph (circles) represents the low-level exposure and the lower graph 
(squares) represents the high-level exposure. MHR remained fairly constant during 
the control and glycerol-formal periods in the low-level experiment. There was an ob­
servable decrease in MHR immediately following exposure. There was a statistically 
significant difference (a = O.Ob. MSD = 11.6) between C'l.C'o.C .^Gi.Go' and G'g 
vs. Di and Z)2 (a, b and c groupings for MHR column in Table 5.1). Further, there 
were no statistically significant differences between G'3 and D^ (c grouping for MHR 
column in Table 5.1) indicating that there was a statistically significant decrease 
(12%) lasting 20 minutes post exposure and after 30 minutes, MHR had returned to 
pre-exposure (control and glycerol-formal) levels. 
The results of the high-level experiment were similar to those of the low-level case 
(although there was greater variability in MHR during the high-level experiment). 
There was an observable decrease in MHR immediately following exposure. However, 
the Tu key test revealed no statistically significant differences between any period-
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Figure 5.8: Mean arterial pressure (averaged over each minute for all dogs) in con­
trol, glycerol-formal and deltamethrin periods; circles indicate low-level 
(5% LD50 exposure {n=12)\ squares indicate high-level (10% LDgg ex­
posure [n=10)\ range represents standard error 
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blocks. This was not a reasonable conclusion. Thus, a slightly less conservative 
Duncan multiple range test was used for MHR in the high-level exposure (indicated 
by lower case letters in the MHR column in Table 5.2). Applying this test, there was 
a statistically significant difference (a = 0.05) between (T'l- Co. Cg, (^2 Gg 
vs. Do and D3 (a and 6 groupings for MHR column in Table 5.2). This indicates that 
there were no significant diff'erences between control and glycerol-formal heart rates 
but after the 10%LD^Q exposure, there was a significant decrease in MHR (13%) 
lasting approximately 20 minutes. Further, there were no statistically significant 
differences between , C'2, C '3, , G'o and G'3 vs. £>3 indicating that heart rate had 
returned to control levels 30 minutes post exposure. 
5.6.3 End tidal COo 
A plot of end tidal COo (pCOo) versus time is shown in Figure 5.10 (see page 
66). The upper graph (circles) represents the low-level exposure and the lower graph 
(squares) represents the high-level exposure. pCOo slowly increases (although not 
statistically significant) during the control and glycerol-formal periods in the low-level 
experiment. There was a statistically significant difference (a = 0.05..U5Z) = 0.4) 
between C'2, (^'3,6']^, G'o and G '3 vs. Di, D-iandD';^ (.4 and B groupings for COo 
column in Table 5.1). This indicated that there was a significant increase (17%) in 
pC02 immediately following the 5% LD5Q exposure and after 30 minutes. pC'02 had 
not returned to control or glycerol-formal pre-exposure levels. 
As was the case with MHR. the results for low- and high-level exposures for 
pC02 were similar. In the 10% LD5Q experiment, pCOo started out nearly a full 1% 
higher than in the low-level exposure experiment. There was a statistically significant 
64 
150 
125 
100 
75 
D C C G G D D C G 
150 
125 
100 
Control Glycerol—Formai Deltamethrin 
75 
0 20 0 30 40 50 60 70 80 90 
Time, minutes 
re 5.9: Mean heart rate (averaged over each minute for all dogs) in control, 
glycerol-formal and deltamethrin periods; circles indicate low-level (5% 
LDgQ exposure {n=12)\ squares indicate high-level (10% LDgQ exposure 
(n=10); range represents standard error 
difference (a = 0.0!y. M S D = 0.6) between , Co. C '3, , G'o and G'3 vs. Do 
and Dg ( .4 and B groupings for CO2 column in Table 5.2). Again, this indicated that 
there was a significant increase in pCOg (14%) immediately following the 10% LD5Q 
exposure and after 30 minutes, pC02 had not returned to control or glycerol-formal 
pre-exposure levels. 
5.6.4 Mean blood flow velocity 
A plot of mean bipod flow velocity (MBFV) versus time is shown in Figure 5.11 
(see page 68). The upper graph (circles) represents the low-level exposure and the 
lower graph (squares) represents the high-level exposure. In the low-level experiment. 
MBFV slowly increases during the control and glycerol-formal periods. However, the 
results of the Tukey test show no significant differences between C'lX'o and C3 
and further, there were no significant differences between Co. Cg, G'g, Do and 
Dg (.4 and B groupings for MBFV column in Table 5.1). There was a statistically 
significant difference between C'l and (a = 0.05,3/51) = 2.8) although there was 
no difference between G2 and This indicated that MBFV did not significantly 
change during the control period; and. with the exception of an increase in the 
middle of the glycerol-formal period (Go), MBFV remained constant until the 5% 
LD5Q exposure. In addition, there was a significant increase in MBFV immediately 
following exposure, and after 10 minutes post exposure, it returned to original control 
and glycerol-formal levels. 
As expected, there is a large degree of variability (large standard error) in each 
of the MBFV plots. In the high-level experiment, there were no significant differences 
between Go, G3, G]^. Do and D3 (G grouping for MBFV column in Table 5.2). 
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Figure .5.10: End tidal CO2 (recorded once every 5 minutes and averaged over all 
dogs) in control, glycerol-formal and deltamethrin periods; circles indi­
cate low-level (5% LDgg exposure {n=12)\ squares indicate high-level 
(10% LD5Q exposure {n=10)\ range represents standard error 
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Further, there were no significant differences between Co, C '3, Go, G'g, Do and £>3 
{B grouping for MBFV column in Table 5.2). There was a statistically significant 
difference (a = 0.05, A/5D = 4.5) between C'l and Di- This indicated that MBFV 
did not significantly change during the control or glycerol-formal periods, but did 
significantly increase immediately following the 10% LD50 exposure. It immediately 
returned to cotitrol and glycerol-formal levels after 10 minutes post exposure. 
5.7 Results of Calculated Parameters 
The next four sections describe the results of the parameters calculated from 
the blood flow velocity waveform. These parameters are systolic-to-diastolic ratio. 
Pourcelout pulsatility index. Gosling pulsatility index and systolic upstroke as defined 
on page 50. 
5.7.1 Systolic-to-diastolic ratio 
.A. plot of systolic-to-diastolic ratio (SDR) versus time is shown in Figure 5.12 
(see page 70). The upper graph (circles) represents the low-level exposure and the 
lower graph (squares) represents the high-level exposure. During the control period of 
the low-level experiment, SDR is highly variable but seems to settle down during the 
glycerol-formal period. This phenomenon probably has little to do with the injection 
of the glycerol-formal because the variability tends to decrease through the control 
phase. The results of the Tukey test showed no significant differences between any 
period-block combinations. .A.pplying Duncan's multiple range test revealed that only 
C'l was significantly different from and Go (a = 0.05). There was an observable 
increase in SDR (although not statistically significant) immediately following the 
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Figure 5.11: Mean blood flow velocity (averaged over each minute for all dogs) 
in control, glycer.ol-formal and deltamethrin periods; circles indicate 
low-level (5% LD50 exposure [n=12)\ squares indicate high-level (10% 
LD50 exposure {n=lO)\ range represents standard error 
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injection of cleltamethrin. It peaked approximately 5 minutes post exposure and 
lasted approximately 8 minutes. 
In the high-level exposure experiment, SDR decreased slowly during the control 
and glycerol-formal periods and then gradually increased in the exposure period. 
There was a large degree of variability in SDR during C'l and Co. The period-block 
groups C'2, C'g. and Cg, , and , G'2, 63, did not significantly differ: however, 
the differences between these groups were statistically significant (a = 0.05, iU5Z) = 
0.18). In addition, there was a statistically significant difference between C'l and 
G '3. This indicates that SDR significantly decreased (12%) through the control and 
glycerol-formal periods and. after exposure to deltamethrin, returned to pre-exposure 
control levels. 
5.7.2 Pourcelout pulsatility index 
A plot of Pourcelout pulsatility index (PPI) versus time is shown in Figure 5.13 
(see page 72). The upper graph (circles) represents the low-level exposure and the 
lower graph (squares) represents the high-level exposure. In the low-level experiment. 
PPI tended to decrease through the control and glycerol-formal periods and then 
to increase in the deltamethrin period. Tukey's test showed that there were no 
statistical differences between C2, C'g,G%, Gg. Gg, and D3 (C grouping for PPI 
column in Table 5.1). There was, however, a statistically significant difference (a = 
0.05, 3/5Z) = 0.05) between and Go (.4 grouping for PPI column in Table 5.1). 
This indicated that the downward trend through the first two periods was significant 
(18%) and, following exposure, PPI increased and returned to the control level. 
A similar trend for PPI was observed in the high-level experiment. There was a 
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Figure 5.12: Systolic-to-diastolic ratio (averaged over each minute for all dogs) 
in control, glycerol-formal and deltamethrin periods; circles indicate 
low-level (5% LD5Q exposure {n=12)\ squares indicate high-level (10% 
LD5Q exposure [n=10)\ range represents standard error 
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statistically significant difference between C'l and G'g (a = O.Oo. MSD = 0.05). In 
addition, the period-block pairs C'l and €'2-, C'2 and C '3, C3 and 6']^, and and G2 
do not significantly differ individually; however, the difference between these pairs 
was statistically significant (a = O.Ob, MSD = 0.05). Thus, as in the 0% LD^q  case, 
the decrease in PPI, through the control and glycerol-formal periods, was significant 
(22%), and, after the 10% LD^g exposure, PPI increased and returned to the control 
level. 
5.7.3 Gosling pulsatility index 
A plot of Gosling pulsatility index (GPI) versus time is shown in Figure 5.14 
(see page 74). The upper graph (circles) represents the low-level exposure and the 
lower graph (squares) represents the high-level exposure. The trend in the GPI 
data paralleled that of the PPI data; that is, in the control and glycerol-formal 
periods of both the low- and high-level exposure experiments, the GPI decreased 
and then increased during the deltamethrin period. In the low-level experiment, 
there was a statistically, significant difference (a = 0.05, A/5Z? = 0.14) between C'l 
vs. Gi^Go Gg (A and B groupings for GPI column in Table 5.1). There 
were no statistically significant differences between Co, Cg, Go. G'g, Do and 
Dg. Thus, GPI significantly decreases (26%) through the control and glycerol-formal 
periods and then increases back to pre-exposure control levels during the deltamethrin 
period. 
In the high-level experiment, the period-block groups . Co. C'g. and Co. C3. . 
and C3, Go. and Gj^, G2, G '3, did not significantly differ individually; however, 
the differences between these groups were statistically significant (a = O.Qô. M S D = 
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Figure 5.13: Pourcelout puisatility index (averaged over each minute for all dogs) 
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low-level (5% LDgg exposure (n=12); squares indicate high-level (10% 
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0.10). In addition, there was a statistically significant difference between and 
G-^. This indicated that GPI significantly decreased (27%) through the control and 
glycerol-formal periods, and after exposure to deltamethrin, returned to pre-exposure 
control levels. 
5.7.4 Systolic upstroke 
A plot of systolic upstroke (SU) versus time is shown in Figure 5.15 (see page 
75). The upper graph (circles) represents the low-level exposure and the lower graph 
(squares) represents the high-level exposure. Systolic upstroke is really the mean 
acceleration of the blood from diastole to peak systole. SU-is quite chaotic in all three 
periods in each experiment. There was an observable increase in SU immediately 
following exposure. The results of the Duncan test indicated that the only period-
blocks that were significantly different (a = 0.05, M5Z? — 30.92) were C'l and D-j-
There were no other significant differences thus there was no consistent trend in SU 
through the low-level experiment. 
In the high-level experiment, the Tu key test revealed no significant differences 
between any period-block combinations. Applying a Duncan's multiple range test on 
the high-level SU data indicated that there were statistically significant differences 
(a = 0.05) between Gi vs. Di and Do (a and 6 groupings for SU column in Table 5.2). 
Further, there were no statistically significant differences between C'j. To. Cg, . Go 
and G^. This showed that there were no significant changes in systolic upstroke 
through the control and glycerol-formal periods and there was a significant increase 
(93%) in SU for 20 minutes post exposure. SU returned to the pre-exposure control 
level after 30 minutes post exposure. 
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6. DISCUSSION 
Each year, thousands of new chemicals are developed and many may eventually 
come into contact with people on the job or simply through every day activities. 
Although every effort is made to ensure that each chemical is safe for human expo­
sure, any new testing procedure that may potentially detect subtle biological changes 
occurring before clinical symptoms are observed would certainly be worth further in­
vestigation. If these subtle changes can be detected early enough, perhaps the chance 
of permanent damage occurring could be reduced or even eliminated completely. 
Transcranial Doppler sonography has been well established as a noninvasive and 
cost effective means of measuring cerebral blood flow in man. Although the use of 
TCD in animals has been limited, pilot work indicated that CBF can be measured 
by TCD in normal greyhound dogs. Further, it was shown that manipulations of 
CBF (using CO2) can be detected using TCD. Deltamethrin had been previously 
shown to increase CBF in rats as determined by other techniques. The purpose of 
the proposed study was to determine whether: 
• Deltamethrin increases cerebral blood flow in a higher mammal (i.e., a grey­
hound dog), and whether 
• Transcranial Doppler sonography can detect changes in CBF at very low expo­
sure levels. 
1 1  
Although no data was obtained for the conscious dog experiments, the uncon­
scious animal experiments did provide some useful information. These results are 
summarized in Table 6.1. With respect to control levels, glycerol-formal alone did 
not exhibit any significant effects on any of the physiological parameters measured. 
However, there was a significant decrease in SDR, PPI and GPI associated with the 
administration of glycerol-formal. This suggests that the shape of the blood flow ve­
locity waveform changes in the presence of glycerol-formal without any corresponding 
changes in any directly measured physiological parameters. Specifically, a decrease 
in pulsatility and systolic-to-diastolic ratio suggest that the amplitude of the BFV 
waveform had diminished with no corresponding change in MBFV. This result would 
have not been known without the use of TCD to continuously measure the blood 
flow velocity waveform. It is possible that the glycerol-formal is acting directly on 
the cerebral vessels (specifically the MCA) by irritating the lumenal surface and caus­
ing the vessels to become less compliant. .A.utoregulation would act to maintain mean 
flow even in the presence of these waveform alterations. 
After exposure to deltamethrin. there is a significant increase in MBFV lasting 
10 minutes post exposure, a significant increase in MAP and decrease in MHR each 
lasting 20 minutes post exposure and a significant increase in pCOo lasting at least 
30 minutes post exposure. The increase in MBFV agrees with previously obtained 
data from rats for rC'BF [7}. In addition, significant decreases in heart rate and 
increases in pC02 and mean arterial pressure were observed during this same post 
exposure period indicating that the deltamethrin was having systemic effects on the 
cardiovascular and cerebrovascular systems. Further, this data is collaborated by 
circulating deltamethrin concentrations which peaked at approximately 5 minutes 
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Table 6.1: Summary of qualitative results of both low- and high-level experiments 
(N/C denotes no change with respect to control) 
Control Gly-For 5% LD^n i  10% LD^o Duration ' 
MBFV — N/C Î (13%) i T (21%) 10 min 
MAP — N/C N/C T (19%) 20 min i 
MHR — N/C 1 (12%) i (13%) 20 min I 
pC02 N/C Î (1T%) T (14%) > 30 min ^ 
SDR i  (41%,12%) N/C N/C 
PPI i  (18%,22%) N/C N/C 
GPI 1 (26%,2T%) N/C ! N/C 
SU -  ! N/C T (65%) I 1(93%) 1 20 min i  
post exposure. 
SDR, PPI and GPI returned to control levels following the administration of 
deltamethrin. Changes in these parameters suggest that there were actual changes in 
the shape of the blood flow velocity waveform occurring after deltamethrin exposure. 
The shape of the BFV waveform depends on a variety of factors including CBF resis­
tance downstream (which is a function of glucose metabolic rate), vessel compliance 
and intracranial pressure. If CBF in the MCA increased while at the same time there 
was a decrease in heart rate, then not only would the mean BFV increase, but also 
the pulsatility would increase as evidenced by an increase in SDR, PPI and GPI. 
There are several points in the methodology used in this experiment that may 
be improved upon in the future. First of all, the biggest question is anesthesia. 
Ideally, anesthesia should be eliminated completely from this experiment. Perhaps 
improvements could be made in the sling and helmet devices to enable restraint of 
a conscious dog for longer periods of time. In lieu of this, a gas anesthesia monitor 
may be used to more precisely control the level of anesthesia during experiments. 
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Also, while verification of TC'D signals by traditional methods is certainly adequate 
in human clinical research, perhaps a more precise method should be developed to 
quantitate probe location. This is especially true in the dog where cerebral vessels are 
smaller and closer together, and the spectral broadening effect is even more promi­
nent. Further, it would be useful to try lowering the exposure level of deltamethrin 
to 2.5% or perhaps even 1% of the LD^q  to determine if changes in MBFV could be 
detected by TCD at these very low levels. 
Finally, this study showed that not only were there changes in the cerebrovascular 
system due to deltamethrin but systemic changes in the cardiovascular system as 
well. To separate these effects, it would be necessary to measure a systemic blood 
flow parameter, i.e., cardiac output, or. ideally, blood flow in the carotid artery 
ipsilateral to the MCA being insonated by the TCD. Then, if there was a change in 
systemic blood flow caused by deltamethrin, this could be measured independently of 
blood flow velocity in the MC.A. Perhaps additional parameters of the BFV waveform 
may be related to the cerebrovascular system. For example, systolic upstroke (or 
acceleration) is related to the force of contraction of the heart. The downslope of the 
BFV waveform is related to the downstream resistance or, in this case, the vascular 
resistance of the brain. It would be of interest to consider the effects of deltamethrin 
on the downstroke of the BFV waveform as a way to further understand how the 
brain reacts to a toxic substance. 
TCD seems to have great potential as a screening methodology: however, prior 
to these experiments, it had not been used with animals nor had it been applied 
in the field of toxicology. In this research, it has been shown that TCD is sensitive 
enough to measure alterations in cerebral blood flow even when no other measurable 
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systemic changes occur. It is hoped that TCD may soon become a routinely used 
screening procedure for detecting the early effects of known (and perhaps even un­
known) substances on people subjected to potentially hazardous materials at home 
or in the workplace. 
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9. APPENDIX A: CANNULA CONSTRUCTION 
Materials List 
From Braintree Scientific, Inc., Braintree, MA: 
1. RPC-080-18 Renapulse rigid catheter kit used for artery. 
2 .  MRP-080-18 Micro-Renathane compliant infusion catheter kit for vein. 
3. SCS-2 red stopcocks. 
4. SCS-2 blue" stopcocks. 
5. Polysciences, Inc. 3813 TDMAC-Heparin 7% (25ml). 
Other Materials Used: 
1. Dacron felt. 
2. Silastic glue. 
3. 32 gauge stainless steel wire. 
4. Silastic tubing (0.035 I.D., 0.010 wall thickness). 
5. Zip Bond glue (Cole-Parmer) Cat. No. L-08776-00 1 oz. bottle. 
6. 3-0 Mersiline. 
Construction 
1. Cut a rectangular piece of Dacron felt 1^ inches long and wide enough to wrap 
around the cannula 1^ times. 
2. Cut a piece of stainless steel wire 12-18 inches long. Wrap the wire around the 
cannula (under the Dacron pad) and anchor the Dacron pad to the cannula. 
Place the Dacron pad about 1 inch from the bottom of the light blue (winged) 
plastic hub on the cannula. 
3. Snugly wrap the stainless steel wire around the cannula tubing in the area 
where the Dacron pad will be placed. Make sure the pad will completely cover 
the wire. Tie the wire to itself, leaving two tails, each about 3 inches long. 
4. Wrap the Dacron felt around the cannula Ig times. Tape the pad shut and 
remove it from the tubing so that it can be sutured closed away from tubing 
(to avoid puncturing cannula). 
•5. Suture the pad closed with 3-0 Mersilene. Attach a suture needle to the end 
of the stainless steel wire tails on the cannula and insert the needle inside the 
sutured Dacron pad. Push the needle and wires through the pad. Thread the 
end of the cannula through the Dacron pad and bring the pad up to just below 
the wrapped wire. Apply a layer of Silastic glue all around the tubing and wire 
in an area which will be completely covered by Dacron pad. Immediately slide 
the pad over the glue, wire and tubing. Wrap wire tails around outside of the 
pad and tie. Air dry Silastic glue for 24 hours. 
6. To make a flexible tip on the distal end of the venous cannula, cut a 2^ inch 
piece of Silastic tubing and immerse in Xylene for 2-3 min. .After removing the 
Silastic tubing from the Xylene, immediately pull the Silastic over the end of 
the cannula tubing. Cover the distal inches of the venous cannula leaving 
an additional 1 inch of Silastic tubing extending beyond the end of the cannula 
tip. Do not place a Silastic tip on the arterial cannula. 
7. Next, coat the inside of both cannulas with TDMAC-Heparin. Using a sy­
ringe filled with TDM AC-Heparin and a blunt needle on the syringe, inject the 
TDMAC-Heparin into each cannula (use gloves and a fume hood). Leave the 
TDMAC-Heparin in cannula for 1 minute. Remove the heparin from cannula. 
Attach the cannula to the end of an air hose and run a stream of air through 
the cannula overnight. 
8. After the cannula is air-dried, glue the 3-way stopcock (blue for venous, red 
for arterial) to the cannula with Zip-Bond glue. .After the Zip-Bond is dry. gas 
sterilize the cannulas using ethylene oxcide. 
9. IMPORTANT - The plastic 3-way stopcocks must be glued on a/<er the TDM.A.C-
Heparin has been added and dried. If the TDMAC-Heparin is added after the 
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stopcocks have been glued, the solvent in the TDMAC-Heparin will dissolve 
the stopcocks. 
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10. APPENDIX B; CANNULA IMPLANTATION 
1. Initially make sure the cannulas are filled with fluid (non-heparinized saline) 
and there are no air bubbles in the lumen. Be sure the stopcocks are securely in 
the ofl" position. Place a sterile drape under the neck area of the animal before 
surgery starts. This area will be redraped later. 
2. With the animal in right lateral recumbency, make an 8 cm skin incision on the 
ventral midline of the neck. With gentle blunt dissection, expose the muscles 
in the neck area so they can be seen but do not cut through or disrupt them. 
Using scissors, make a pocket under the skin on the proximal ("up") side about 
the size of a half dollar coin. 
3. Without rnoving the animal, make a 4-5 cm incision on the dorsal midline of 
the neck. Form a pocket under the skin about the size of a quarter by each side 
of the anterior end of the incision. Pass an aluminum tube from the posterior 
end of the incision, under the skin, to the ventral neck area and exit through 
the first incision. Pass the venous cannula through the tubing as far as possible 
and then pull the tube out through the ventral skin incision while holding 
the cannula stationary. The cannula should be under the skin connecting the 
two surgical sites. Next, starting at the anterior end of the incision, repeat the 
process for the placement of the arterial cannula. Form a pocket for the Dacron 
sleeve on one side of the midline. Place a loop of tubing in the anterior pocket 
and form another pocket under the skin for the sleeve of the other cannula on 
the opposite side of the midUne. 
4. Using a stainless steel suture (4-0), pass the attached needle through the end 
of the sleeve next to the valve, then through a layer of the skin (without going 
completely through), and return to the sleeve to take another pass. Pull the 
suture snugly, but not too tight, and tie. The knot should be buried when the 
incicion is closed. Repeat the procedure for the other cannula. 
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5. After anchoring the cannula, suture the skin with an interrupted suture pattern 
using the same suture material used for the skin closure. Draw the skin up over 
the cannula sleeves and close the skin on the back of the neck. Loosely place 
the sutures about 3-4 mm apart. 
6. Roll the dog over so that it is now in dorsal recumbancy. Redrape as needed 
and use a new set of surgical instruments on the new surgical site. Find the 
line separating the muscles on the ventral surface of the neck. Bluntly dissect 
along this line down to the trachea; a 6-7 cm exposure is required. 
7. The carotid arteries lie on either side of and slightly below the trachea. Gently 
dissect around a carotid artery to expose about 3-4 cm of vessel. Separate the 
nerve from the vessel sheath but don't damage the nerve in any way. After the 
artery is free, expose and isolate 4-5 cm of the jugular vein (located just under 
the skin). 
8. After the vein is exposed, prepare to cannulate it first. Select the site for the 
cannulation. Estimate the distance from that site to the third intercostal space 
(approximately the length of cannula placed inside the vessel). Leave as much 
connective tissue on the vessel wall as possible while still having a workable 
area for cannulation. Now put in a simple purse string suture pattern (twice 
the cannula diameter) using 3-0 Mersilene in the surface of the vessel. Enter 
only connective tissue and vessel wall being careful not to enter the lumen. 
Make one throw of a surgeons knot but do not draw it tight (clamp the end 
in a hemostat). Enter the vein with a cannula introducer (or an 18 gauge 
needle with the tip bent at a 80 degree angle). Use this to make a hole in 
the vessel wall by carefully placing the point of the needle in the center of the 
area delineated by the purse string. Without removing the introducer, insert 
the venous cannula. Grasp the small silastic tip gently between two fingers 
(or with small tip thumb forceps) and work the cannula into the vessel. If the 
introducer should come out, use the plastic cannula introducer to reenter the 
original opening. Place the venous cannula in the vessel lumen to the estimated 
length. Draw the purse string up snugly around the cannula and tie securely 
(using many throws). Next, place 6-8 clove hitch knots around the cannula 
with the same suture. Finally, anchor the cannula to some connective tissue 
2-3 cm away from the vessel. 
9. To cannulate the artery, follow the same procedure outlined above with the 
. following exceptions: 
(a) Use a vascular clamp (or two bulldpg clamps) to control the bleeding. 
Remember that the carotid artery is a high pressure vessel. 
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(b) After inserting the cannula tip into the lumen, release the clamp just 
enough to pass the cannula into the vessel the remaining distance. 
(c) All hemorrhage must be controlled by the purse string suture. Remove all 
clamps and gently move the cannula to test for leaks. 
10. Close the skin completely over the cannulas after placing the excess tubing in 
the prepared pocket under the skin. 
11. After the surgical procedure has been completed, flush both cannulas with 
heparinized saline. Be sure to close the valve while the heparin injection is 
being made; this will prevent blood from entering the cannula tip and clotting. 
Apply furacin powder (or paste) to the cannula entrance site and wrap the area 
securely using gauze or an orthopedic stocking. Flush both cannulas daily with 
heprinized saline to prevent clotting. 
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11. APPENDIX C: TCD DATA ANALYSIS PROGRAM 
The following program takes the blood pressure and blood flow velocity wave­
forms from the Codas software and processes the data as described in Chapters 4 
and 5. 
) ) >  I  ) > )  I  > > ) > )  I  ) > ) } I ] ) ) I  I ) ] I ) > ) > ) > > > > >  I  > ) > > > ) > ) ) ) >  I  I ) ) I  I  I  ) ) > )  I  ) > ) ) )  I  > )  )  
' TCD Data Analysis Package by Michael Drues 
' March, 1992, Iowa State University Dept. of Biomedical Engineering 
' File Name Convension for OPEN/CLOSE: 
) 
' #1 —> original data (i.e., CONTROL.TXT) 
' #2 —> one minute data files from #1 (i.e., CTRLOOO.TXT) 
' #3 --> one heart beat files from #2 (i.e., WAVEOOO.TXT) 
' #4 --> result data files (i.e., RESULOOO.TXT) 
' #5 —> heart beat files BEFORE checking mean+/-s.d. (TEMPOOO.TXT) 
' #6 —> Codas data denoting diastolic points (i.e., CONTROL.L2) 
' #7 —> summary of diastolic, systolic, MAP and HR for each minute 
' #8 —> Stats on filtered wave data, STATS.TXT 
) 
' Colors : 
' 13 - purple ; 14 - yellow ; 12 - red ; 10 - green 
> )  I  ) )  t  ) ) ) ) > >  t  ) } ) > > ) ) > ) 1 ) ) ) ) ) I  I  > ) ) ) ) > ) ) I  > ) ) > ) ) I ) > ) ) > ) )  I  ) > ) )  I  ) ) ) > ) ) ) > > )  )  
starttime = TIMER 
DIM observation(200), numobs(200), bfvpt(200), bppt(200), 
dia(200), sys(200), map(200), hr(200) 
again : 
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GOSUB myscreen 
COLOR 14 
LOCATE 13, 35: PRINT "1 = Control" 
LOCATE 14, 35: PRINT "2  = Glycerol-Formal" 
LOCATE 15, 35 : PRINT "3 = Deltamethrin" 
LOCATE 10, 25: INPUT "Select one:"; datatype 
IF datatype = 1 THEN datatype$ = "CONTROL" 
IF datatype = 2 THEN datatype$ = "GLY" 
IF datatype = 3 THEN datatype# = "DELTA" 
IF datatypeOl AND datatype<>2 AND datatype<>3 THEN GOTO again 
GOSUB myscreen 
COLOR 14: LOCATE 10, 25 
PRINT "For the datatype#; " period," 
LOCATE 12, 10 
INPUT "Enter path to FIND data files [D:\DATA\TCD\DATA\] > "; 
datapath# 
BEEP 
IF datapath# = "" THEN datapath# = "D:\DATA\TCD\DATA\" 
LOCATE 14, 10 
INPUT "Enter path to SAVE results files [D:\DATA\TCD\RESULTS\] 
> "; respath# 
BEEP 
IF respath# = "" THEN respath# = "D:\DATA\TCD\RESULTS\" 
LOCATE 16, 10 
INPUT "Enter path to SAVE temporary files [E:\TEMP\] > "; 
temppath# 
BEEP 
IF temppath# = "" THEN temppath# = "E:\TEMP\" 
GOSUB myscreen 
COLOR 14: LOCATE 10, 25 
PRINT "Enter parameters (DEFAULT):" 
COLOR 12 
LOCATE 12, 25 
INPUT "Enter sampling rate (50 Hz): "; samplerate 
IF samplerate = 0 THEN samplerate = 50 
data# = datapath# + datatype# + ".TXT" 
OPEN data# FOR INPUT AS #1 
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FOR i=l TO 3: LINE INPUT #1, j\mk$: NEXT i: junk$ = "" 
) ) ) } ) ) ) ) ) } ) ) ) } ) ) ) } ) ) ) > ) ) ) ) ) ) ) ) ) } } ) ) ) ) ) ) ) } ) ) } ) ) ) ) ) ) ) ) ) ) ) ) ) } } ) ) ) ) ) } >  i  i  >  )  
' Break up original data file into one minute files 
' i.e, CONTROL.TXT —> CTRLOOO.TXT, CTRL001.TXT, ... 
) ) ) ) ) } ) ) ) }  i  } }  i  }  i  ) } ) ) > ) } } ) ) ) ) } ) ) )  i  ) ) } ) ) )  i  i  ) } ) )  i  ) ) ) } ) ) ) ) } ) ) ) ) ) ) > ) ) )  i  ) > )  )  
minute = 0 
obs = 1 
totalobs = 1 
numf iles = 0 
breakup : 
IF minute >= 0 AND minute <= 9 THEN outfile$ = datapath$ + 
"CTRLOO" + LTRIM$(STR$(minute)) +. ".TXT" 
IF minute >= 10 AND minute <= 99 THEN outfile$ = datapath$ + 
"CTRLO" + LTRIM$(STR$(minute)) + ".TXT" 
IF minute >= 100 AND minute <= 999 THEN outfile$ = datapath$ + 
"CTRL" + LTRIM$(STR$(minute)) + ".TXT" 
IF minute > 999 THEN GOSUB myscreen: LOCATE 20, 25: PRINT 
"ERROR DETECTED - To many files!": GOTO finish 
OPEN outfile$ FOR OUTPUT AS #2 
GOSUB myscreen 
COLOR 12: LOCATE 11. 25: PRINT "Extracting "; outfile$ 
LOCATE 12, 30: PRINT " from "; data$ 
COLOR 10 
LOCATE 15, 25: PRINT USING "Total time analyzed thus far: 
###### minutes"; minute; 
LOCATE 16, 25: PRINT USING "Total observations thus far: 
######### observations"; totalobs 
DO WHILE obs / samplerate <= 60 
INPUT #1, bfv, bp 
IF EOF(l) THEN GOTO continue: 
PRINT #2, totalobs, bfv, bp 
obs = obs + 1 
totalobs = totalobs + 1 
LOOP 
numfiles = numfiles + 1 
IF numfiles = 31 THEN GOTO continue 
minute = minute + 1 
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obs = 1 
CLOSE #2 
GOTO breakup 
) ) ) )  I  ) ) ) ) ) ) } ) > > ) } } > > > } > ) > > ) > } > > > > ) ) > } ) ) } > ) > ) ) > } > ) } > ) > ) ) > > > } ) } ) ) > ) ) ) ) )  }  
' Use Codas *.L2 file to separate each 1 minute file into 1 heart 
' cycle files i.e., 
' CONTROL.L2 + CTRLOOO.TXT. ... --> WAVEOOO.TXT, WAVE001.TXT. ... 
I >  I  1 1 ) > > > I > ) I ) I  I >  I  >  I ) I ) I ) > > I  I  I  I > > I >  I  I  I >  I ) I  I  I  I  >  I  ) > > > >  I  I  ) ) >  I  > >  I  ) >  I  I  ) >  I  )  >  
continue:. 
GOSUB myscreen 
BEEP: BEEP: BEEP 
CLOSE 
COLOR 12 
LOCATE 10, 25: PRINT USING "Total number of files = 
#####"; numfiles 
LOCATE 11, 25: PRINT USING "Total number of observations = 
#####"; totalobs 
summary$ = respath$ + "SUMMARY.TXT" 
OPEN summary$ FOR OUTPUT AS #7 
OPEN datapath# + datatype# + ".L2" FOR INPUT AS #6 
FOR i = 1 TO 9; LINE INPUT #6, junk$: NEXT i: junk$ = "" 
k = 0 
obs = 1 
minute = 0 
FOR result = 0 TO numfiles 
IF k = numfiles THEN GOTO finish 
IF result >= 0 AND result <= 9 THEN results# = respath# + 
"RESULOO" + LTRIM$(STR$(result)) + ".TXT" 
IF result >= 10 AND result <= 99 THEN results# = respath# + 
"RESULO" + LTRIM$(STR$(result)) + ".TXT" 
IF result >= 100 AND result <= 999 THEN results# = respath# + 
"RESUL" + LTRIM#(STR#(result)) + ".TXT" 
IF result > 999 THEN GOSUB myscreen: LOCATE 20, 25: PRINT 
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"ERROR DETECTED - To many files!": GOTO finish 
OPEN results$ FOR OUTPUT AS #4 
IF k >= 0 AND k <= 9 THEN infile$ = datapath$ 
+ "CTRLOO" + LTRIM$(STR$(k)) + ".TXT" 
IF k >= 10 AND k <= 99 THEN infile$ = 
datapath$+ "CTRLO'.' + LTRIM$ (STR$ (k) ) + ".TXT" 
IF k >= 100 AND k <= 999 THEN infile$ = 
datapaths + "CTRL" + LTRIM$(STR$(k)) + ".TXT" 
IF k > 999 THEN GOSUB myscreen: LOCATE 20, 25: 
PRINT "ERROR DETECTED - To many files!": GOTO 
finish 
OPEN infile$ FOR INPUT AS #2 
INPUT #6, diastolic, systolic, map, hr, 
diaobs, sysobs 
DO WHILE obs < diaobs 'move to begining of 
heartbeat 
INPUT #2, obs, bfv, bp 
IF EOF(2) GOTO continues 
LOOP 
continues: 
cycle = 1 
z = 1 
waves : 
INPUT #6, diastolic, systolic, map, hr, diaobs, sysobs 
IF EOF(6) THEN GOTO continue2 
dia(z) = diastolic 
sys(z) = systolic 
map(z) = map 
hr(z) = hr 
z = z + 1 
n = 1 
IF cycle >= 0 AND cycle <= 9 THEN outfile2$ = 
temppath$+ "TEMPOO" + LTRIM$(STR$(cycle)) + ".TXT" 
IF cycle >= 10 AND cycle <= 99 THEN outfile2$ = 
temppath$ + "TEMPO" + LTRIM$(STR$(cycle)) + ".TXT" 
IF cycle >= 100 AND cycle <= 999 THEN outfile2$ = 
temppath$ + "TEMP" + LTRIM$(STR$(cycle)) + ".TXT" 
IF cycle > 999 THEN GOSUB myscreen: LOCATE 20, 25: 
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PRINT "ERROR DETECTED - To many files!": GOTO 
finish 
OPEN outfile2$ FOR OUTPUT AS #3 
DO WHILE obs < diaobs 'identify heartbeat cycle 
COLOR 10 
LOCATE 13, 25; PRINT "Taking data from "; 
infile$ 
COLOR 14 
LOCATE 15, 25: PRINT USING "Current 
observation is ######"; obs 
LOCATE 16, 25: PRINT USING "Next heartbeat 
begins at ######"; diaobs 
COLOR 12 
LOCATE 18, 25: PRINT "Saving in file "; 
outfile2$ 
INPUT #2, obs, bfv, bp 
IF EOF(2) THEN GOTO continue2 
PRINT #3, n, bfv, bp 
n = n + 1 
LOOP 
observation(cycle) = n - 1 
COLOR 10 
LOCATE 20, 25: PRINT "Number of heart cycles is "; 
cycle 
LOCATE 21, 25: PRINT "Number observations in this 
heartbeat : "; n - 1 
CLOSE #3 
cycle = cycle + 1 
GOTO waves 
continue2: 
CLOSE #2 
CLOSE #3 
FOR m = 1 TO z - 1 
diatotal = dia(m) + diatotal 
systotal = sys(m) + systotal 
maptotal = map(m) + maptotal 
hrtotal = hr(m) + hrtotal 
NEXT m 
diamean = diatotal / (z - 1) 
sysmean = systotal / (z - 1) 
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mapmean = maptotal / (z - 1) 
hrmean = hrtotal / (z - 1) 
FOR m = 1 TO z - 1 
diatempl = (dia(m) - diamean) " 2 
diatemp2 = diatempl + diatemp2 
systempl = (sys(m) - sysmean) " 2 
systemp2 = systempl + systemp2 
maptempl = (map(m) - mapmeem) " 2 
maptemp2 = maptempl + maptemp2 
hrtempl = (hr(m) - hrmeein) " 2 
hrtemp2 = hrtempl + hrtemp2 
NEXT m 
diadev = SqR(diatemp2 / (z - 1)) 
sysdev = SqR(systemp2 / (z - 1))' 
mapdev = SqR(maptemp2 / (z - 1)) 
hrdev = SQR(hrtemp2 / (z - 1)) 
diatotal = 0: systotal = 0: maptotal = 0: hrtotal = 0 
diatempl = 0: diatemp2 = 0 
systempl = 0: systemp2 = 0 
maptempl = 0 : maptemp2 = 0 
hrtempl = 0: hrtemp2 = 0 
FOR m = 1 TO z 
dia(m) = 0: sys(m) = 0: map(m) = 0: hr(m) = 0 
NEXT m 
GOSUB myscreen 
LOCATE 10, 20 
PRINT "For minute minute 
LOCATE 12, 25: PRINT USING "Mean diastolic pressure = ###.# 
+/- ##.## mmHg"; diamean; diadev 
LOCATE 13, 25: PRINT USING "Mean systolic pressure = ###.# +/-
##.## mmHg"; sysmean; sysdev 
LOCATE 14, 25: PRINT USING "Mean arterial pressure = ###.# +/-
##.## mmHg"; mapmean; mapdev 
LOCATE 15, 25: PRINT USING "Mean heart rate = ###.# +/- ##. ## 
bpm"; hrmean; hrdev 
LOCATE 17, 25: PRINT "Saving means eind deviations in " ; 
summary$ 
PRINT #7, minute; rejects; diamean; diadev; 
sysmeein; ","; sysdev; mapmean ; mapdev; 
hrmean; ","; hrdev 
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minute = minute + 1 
) )  I  1  )  I  I  1 1  j  I  >  I  j  >  I  ) ) >  I  > ) > )  1  I  )  I  I I ) > I  > ) I ) I I  > 1 ) ) > I I  I I  I I ) > I  I I  I >  I I  ) >  I  I  )  I  ) )  I l  >  
' Calculate AVERAGE, STND. DEV., eind RANGE for number of observations 
' in each heart cycle file over the one minute interval. 
J  ) ) }  J  ) ) } } ) ) } ) } ) ) ) ) )  J  J  ) } ) ) ) ) ) ) ) ) ) )  f  )  J  ) )  J  ) ) ) )  J  > } ) ) )  f  ) > ) ) )  t  ) )  J  ) ) ) ) ) ) ) ) )  J  
minimum = observation(l) 
maximum = observation(l) 
FOR i = 1 TO cycle - 1 
total = observation(i) + total 
IF minimum > observation(i) THEN minimum = 
observation(i) 
IF maximum < observation(i) THEN maximum = 
observation(i) 
NEXT i 
average = total / i 
FOR i = 1 TO cycle - 1 
tempi = (observation(i) - average) " 2 
temp2 = temp2 + tempi 
NEXT i 
stnddev = SQR(temp2 / i) 
lowlimit = average - stnddev 
highlimit = average + stnddev 
) ) ) ) ) ) ) ) ) ) ) ) )  J  ) ) ) ) ) ) ) ) ) ) ) } ) ) ) ) ) ) ) ) ) ) ) ) ) )  f  ) ) } ) ) ) ) ) ) ) }  l  ) ) ) ) > )  J  } } ) ) ) ) ) ) )  }  
' Delete heart beats which have no. of obs. outside MEAN +/- S.D. 
' (to minimize phase shifts and remove bad data (i.e., flushing) 
' and rename TEMP*.TXT --> WAVE*.TXT files 
) ) ) ) ) ) > ) ) ) ) } ) ) > } ) ) )  J  ) ) ) >  J  } ) } ) ) ) } ) ) ) ) ) ) ) ) ) ) ) } )  t  ) ) )  f  }  J  ) )  J  ) ) ) } ) ) } ) )  t  ) ) ) )  >  
rejects = 0 
j = 1 
FOR i = 1 TO cycle - 1 
IF i >= 0 AND i <= 9 THEN templ$ = temppath$ + 
"TEMPOO" + LTRIM$(STR$(i)) + ".TXT" 
IF i >= 10 AND i <= 99 THEN templ$ = temppath$ + 
"TEMPO" + LTRIM$(STR$(i)) + ".TXT" 
IF i >= 100 AND i <= 999 THEN templ$ = temppath$ + 
"TEMP" + LTRIM$(STR$(i)) + ".TXT" 
IF i > 999 THEN GOSUB myscreen: LOCATE 20, 25: PRINT 
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"ERROR DETECTED - To many files!": GOTO finish 
IF observation(i) < lowlimit OR observation(i) > 
highlimit THEN GOTO reject: ELSE GOTO accept: 
reject : 
KILL templ$ 
LOCATE 20, 20: PRINT "Deleting templ$ 
rejects = rejects + 1 
GOTO continues 
accept : 
IF j >= 0 AND j <= 9 THEN wavel$ = temppath$ + 
"WAVEOO" + LTRIM$(STR$(j)) + ".TXT" 
IF j >= 10 AND j <= 99 THEN wavel$ = temppath$ + 
"WAVEO" + LTRIM$(STR$(j)) + ".TXT" 
IF j >= 100 AND j <= 999 THEN wavel$ = temppath$ + 
"WAVE" + LTRIM$(STR$(j)) + ".TXT" 
OPEN tempi* FOR INPUT AS #5 
OPEN wavel$ FOR OUTPUT AS #3 
DO WHILE NOT EOF(5) 
INPUT #5, n, bfv, bp 
PRINT #3, n, bfv, bp 
LOOP 
CLOSE #3 
CLOSE #5 
j = j + 1 
KILL templ$ 
LOCATE 22, 20: PRINT "Renaming templ$; " as 
wavel$ 
continue9: 
NEXT i 
rejects = rejects / (cycle - 1) * 100 
cycle = j 
maximum = highlimit 
GOSUB myscreen 
) ) ) ) ) ) ) ) ) ) ) } ) }  J  ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )  i  f  i  ) ) ) }  i  } ) ) ) ) ) } ) ) ) ) > ) ) ) ) } ) ) ) ) } ) ) ) ) ) )  )  
' Count no. of first, second, etc. points across valid heart beats 
) )  i  } ) )  f  ) } ) ) ) ) ) ) ) ) )  i  )  f  ) } )  i  } ) ) ) ) )  t  ) ) > )  i  } } ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )  J  > } ) } ) } ) } } )  )  
LOCATE 10, 10: PRINT "Counting first points, second points, 
etc., in each heartbeat." 
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FOR i = 1 TO cycle - 1 
IF i >= 0 AND i <= 9 THEN filel$ = temppath$ + 
"WAVEOO" + LTRIM$(STR$(i)) + ".TXT" 
IF i >= 10 AND i <= 99 THEN filel$ = temppath$ + 
"WAVED" + LTRIM$(STR$(i)) + ".TXT" 
IF i >= 100 AND i <= 999 THEN filel$ = temppath$ + 
"WAVE" + LTRIM$(STR$(i)) + ".TXT" 
IF i > 999 THEN GOSUB myscreen: LOCATE 20, 25; PRINT 
"ERROR DETECTED - To many files!": GOTO finish 
OPEN filel$ FOR INPUT AS #3 
pts = 1 
DO WHILE NOT EOF(3) 
INPUT #3, obs, bfv, bp 
numobs(pts) = nuinobs(pts) + 1 
pts = pts + 1 
LOOP 
CLOSE #3 
continue?: 
NEXT i 
} > ) ) ) )  I  >  I  > > ) ) } ) ) ) ) ) I ) > ) ) ) ) J  ) ) >  I ) I ) ) ) ) ) ) I ) I  > > ) I  I  }  I  I  I  I  )  I  I  1 1  I  > )  I  I  ) >  I  I  >  1 1  >  
' Calculate MEAN and S.D. of first, second, third, etc. obs. across 
' all valid heart beat files and store to RESUL*.TXT file 
> > > ) > > ) ) ) ) ) ) > ) ) > ) ) ) ) ) >  1  ) )  I ) ) ) ) )  I  ) ) ) > > ) ) ) > )  I  )  I  ) > > ) )  t  ) ) ) ) ) ) > ) ) ) > ) ) ) ) > >  I  >  
GOSUB myscreen 
FOR pt = 1 TO maximum 
COLOR 14 
LOCATE 13, 25: PRINT USING "Analyzing point ### of 
###": pt; maximum 
FOR i = 1 TO cycle - 1 
IF i >= 0 AND i <= 9 THEN filel$ = temppath$ + 
"WAVEOO" + LTRIM$(STR$(i)) + ".TXT" 
IF i >= 10 AND i <= 99 THEN filel$ = temppath$ 
+ "WAVEO" + LTRIM$(STR$(i)) + ".TXT" 
IF i >= 100 AND i <= 999 THEN filel$ = 
temppathS + "WAVE" + LTRIM$(STR$(i)) + ".TXT" 
IF i > 999 THEN GOSUB myscreen: LOCATE 20, 25: 
PRINT "ERROR DETECTED - To many files!": GOTO 
finish 
OPEN filel$ FOR INPUT AS #3 
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j = 1 
DO WHILE NOT EOF(3) 
INPUT #3, obs, bfv, bp 
IF j = pt THEN GOTO continued 
j = j + 1 
LOOP 
bfvpt(i) = bfv 
bppt(i) = bp 
CLOSE #3 
NEXT i 
IF numobs(pt) = 0 THEN GOTO zero 
FOR i = 1 TO numobs(pt) 
bfvtot = bfvtot + bfvpt(i) 
bptot = bptot- + bppt(i) 
NEXT i 
bfvavg = bfvtot / numobs(pt) 
bpavg = bptot / nuinobs(pt) 
FOR i = 1 TO numobs(pt) 
bfvtempl = (bfvpt(i) - bfvavg) ~ 2 
bfvtemp2 = bfvtemp2 + bfvtempl 
bptempl = (bppt(i) - bpavg) " 2 
bptemp2 = bptemp2 + bptempl 
NEXT i 
bfvdev = SqR(bfvtemp2 / numobs(pt)) 
bpdev = SQR(bptemp2 / numobs(pt)) 
PRINT #4, pt; numobs(pt); bfvavg; 
bfvdev; bpavg; bpdev 
COLOR 10 
LOCATE 10. 25: PRINT USING "Average 
observations/heartbeat = ##.# +/- ##.##"; average; 
stnddev 
LOCATE 11, 25: PRINT USING "Remge of observations = 
### - ###"; minimum; maximum 
continue4: 
continues : 
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COLOR 12 
LOCATE 15, 25: PRINT USING "For point ###,"; pt 
LOCATE 16, 30: PRINT USING "Blood Flow Velocity is 
####.## +/- ##.## cm/sec"; bfvavg; bfvdev 
LOCATE 17, 30: PRINT USING "Blood Pressure is ####.## 
+/- ##.## raitiHg" ; bpavg; bpdev 
LOCATE 18, 30: PRINT "Number of beats containing this 
cycle is "; numobs(pt) 
COLOR 10. 
LOCATE 20, 25: PRINT "Writing results to: "; results$ 
zero : 
bfvtot = 0: bptot = 0 
bfvavg = 0: bpavg = 0 
bfvtempl = 0: bptempl = 0 
bfvtemp2 = 0: bptemp2 = 0 
bfvdev = 0 : bpdev = 0 
FOR i = 1 TO 200 
bfvpt(i) = 0 
bppt(i) = 0 
observation(i) = 0 
NEXT i 
NEXT pt 
cycle = 1 
n = 1 
CLOSE #4 
CLOSE #2 
k = k + 1 
KILL temppath$ + "*.TXT" 
GOSUB myscreen 
FOR i = 1 TO 200 
numobs(i) = 0 
NEXT i 
total = 0 
maximum = 0 : minimum = 0 
tempi = 0: temp2 = 0 
average = 0 : stnddev = 0 
lowlimit = 0: highlimit = 0 
NEXT result 
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finish: 
OPEN temppath$ + "TEMP.TXT" FOR OUTPUT AS #10 
PRINT #10, numfiles 
CLOSE 
BEEP: BEEP: BEEP 
END 
myscreen: 
SCREEN 12: CLS 
LINE (0, 0)-(639, 399), 9. B: LINE (1, l)-(638, 398), 9, B 
COLOR 13: LOCATE 6, 20 
PRINT "TCD Data Analysis Package by Michael Drues" 
LOCATE 24, 50: PRINT USING "Execution time = #####.## min."; 
(TIMER - starttime) / 60 
COLOR 10 
BEEP 
RETURN 
mycontinue : 
COLOR 12 
LOCATE 24, 55: PRINT "Continue (Y/n): "; INKEY$ 
IF INKEY$ <> "" OR INKEY$ <> "Y" OR IMKEY$ <> "y" THEN GOTO 
finish 
COLOR 10 
RETURN 
The next program takes the results of the last program and calculates the SDR. 
PPI, GPI and SU from the BFV waveform. 
}  t  ) } ) ) )  f  ) ) ) ) ) ) ) ) } ) ) ) ) ) } ) ) } ) )  i  ) ) )  f  ) } ) > } ) } ) > ) ) ) ) } ) ) ) } )  t  ) ) ) ) ) } )  i  )  t  ) > ) )  t  )  )  
' Calculate wave parameters on filtered data (i.e., RESUL000.TXT, ...) 
) ) > } ) ) )  i  ) ) } ) ) )  i  ) } ) ) ) }  t  )  i  i  J  } } ) } > ) } ) ) ) ) ) ) ) } ) ) ) )  J  ) }  i  )  i  ) } ) } ) )  i  ) ) } ) ) } ) ) ) ) )  )  
• DIM bfv(300), bp(300), m(lOO) 
CLS 
OPEN "D:\DATA\TCD\DATA\TEMP.TXT" FOR INPUT AS #1 
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INPUT #1, numfiles 
CLOSE 
OPEN "D:\DATA\TCD\RESULTS\STATS.TXT" FOR OUTPUT AS #1 
FOR result = 0 TO numfiles - 1 
PRINT "Minute = result 
IF result >= 0 AND result <= 9 THEN results$ = 
"D:\DATA\TCD\RESULTS\RESULOO" + 
LTRIM$(STR$(result)) + ".TXT" 
IF result >= 10 AND result <= 99 THEN results$ = 
"D:\DATA\TCD\RESULTS\RESULO" + 
LTRIM$(STR$(result)) + ".TXT" 
IF result >= 100 AND result <= 999 THEN results# = 
"D:\DATA\TCD\RESULTS\RESUL" + LTRIM$(STR$(result)) 
+ ".TXT" 
OPEN results# FOR INPUT AS #2 
j = 1 
DO WHILE NOT EOF(2) 
INPUT #2, obs, totobs, bfv, bfverr, bp, bperr 
bfv(j) = bfv 
bp(j) = bp 
j = j + 1 
LOOP 
CLOSE #2 
samples = j - 1 
minbfV = bfv(l) 
maxbfv = bfv(l) 
FOR i = 1 TO samples 
bfvtot = bfv(i) + bfvtot 
bptot = bp(i) + bptot 
IF minbfv>=bfv(i) THEN minbfv=bfv(i): imin = i 
IF maxbfv<=bfv(i) THEN maxbfv=bfv(i): imax = i 
NEXT i 
meanbfv = bfvtot / samples 
meanbp = bptot / samples 
sdratio = maxbfv / minbfv 
ppi = (maxbfv - minbfv) / maxbfv 
gpi = (maxbfv - minbfv) / meanbfv 
j = 1 
FOR i = imin TO imax 
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m(j) = (bfv(i + 1) - bfv(i)) * 50 ' 
(upstroke, cm/sec/sec) 
j = j + 1 
NEXT i 
maxslope = m(l) 
FOR i = i TO j 
IF maxslope <= m(i) THEN maxslope = m(i) 
NEXT i 
upslope = maxslope 
PRINT #1, result; meanbp; meanbfv; 
sdratio; ppi; gpi; maxslope 
FOR i = 1 TO samples : bfv(i) = 0: bp(i) = 0: NEXT i 
bptot = 0: bfvtot = 0: minbfv = 0: maxbfv = 0 
NEXT result 
CLOSE #1 
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12. APPENDIX D: SAS CODE FOR STATISTICAL ANALYSIS 
The foiling is the SAS source code used for preforming the analysis of variance 
on the MBFV, MAP, MHR, pC02, SDR, PPI, GPI and SUS data. Simply change 
the dose and parameter variables for each analysis. 
data ted; 
infile '/home/drues/=stat/=tcd/data.txt' pad missover; 
input measure $ dog $ dose $ period $ minute value; 
if minute > 30 then delete; 
if 1 <= minute <=10 then block = 1 ; 
if 11 <= minute <=20 then block = 2 
if 21 <= minute <=30 then block = 3 
if dose = "High" then delete; 
if measure ne "MBFV" then delete; 
run; 
title 'Mean Blood Flow Velocity for Low Level Experiment'; 
proc sort data = ted; 
by period block dog ; 
run; 
proc means data = ted maxdec=4 mean noprint ; 
by period block dog; 
var value; 
output out=datame£in mean= mvalue; 
run; 
110 
proc sort data = datamean; 
by period block ; 
run; 
proc means data=datamean maxdec=4 noprint; 
by period block; 
var mvalue; 
output out=tempmean mean= mmean sum= smean; 
run; 
proc print data=datamean; 
proc print data=tempmean; 
run; 
proc glm data = datamean ; 
classes period block dog; 
model mvalue = period block dog period*block; 
means period block dog period*block / duncan scheffe Isd tukey ; 
run ; 
data datamean; 
set datameain; 
if period= 'Control' and block= 1 then perblk=l 
if period= 'Control cind block= 2 then perblk=2 
if period= 'Con t ro l '  and block= 3 then perblk=3 
if period= 'Glyfor' and block= 1 then perblk=4 
if period= 'Glyfor' and block= 2 then perblk=5 
if period= 'Glyfor' cind block= 3 then perblk=6 
if period= 'Delta' and block= 1 then perblk=7 
if period= 'Delta' and block= 2 then perblk=8 
if period= 'Delta' and block= 3 then perblk=9 
proc glm data = datameein ; 
classes perblk dog; 
model mvalue = perblk dog; 
means perblk / duncan scheffe Isd tukey ; 
run ; 
